```
=> fil reg
FILE 'REGISTRY' ENTERED AT 09:03:00 ON 14 MAR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   13 MAR 2005  HIGHEST RN 845467-46-1
DICTIONARY FILE UPDATES:  13 MAR 2005  HIGHEST RN 845467-46-1

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> d l19 ide can

L19  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   294849-86-8  REGISTRY
CN   Urea, N-[5-(1,1-dimethylethyl)-2-methylphenyl]-N'-[4-[6-[(3-
     methoxypropyl)methylamino]-3-pyridinyl]-1-naphthalenyl]- (9CI)  (CA INDEX
     NAME)
FS   3D CONCORD
MF   C32 H38 N4 O2
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL
DT.CA  CAplus document type:  Patent
RL.P   Roles from patents:  BIOL (Biological study); PREP (Preparation); USES
       (Uses)
```

PAGE 1-A



PAGE 2-A

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 139:197476

REFERENCE 2: 133:252426

=> d his

(FILE 'HOME' ENTERED AT 08:52:21 ON 14 MAR 2005)
SET COST OFF

FILE 'HCAPLUS' ENTERED AT 08:52:37 ON 14 MAR 2005
L1 3 S (US20040019038 OR US6660732 OR US20020055507 OR US6656933 OR
E CIRILLO P/AU
L2 48 S E3,E6-E8
E BREITFELDER S/AU
L3 19 S E5,E6
E PATEL U/AU
L4 58 S E3,E12,E37,E41,E42
E PROUDFOOT J/AU
L5 261 S E3,E5,E7-E9
E SWINAMER A/AU

```
L6             9 S E4-E6
                 E TAKAHASHI H/AU
L7          1739 S E3-E8,E95-E97
                 E GILMORE T/ AU
L8            44 S E3,E4,E11,E12,E21
                 E SHARMA R/AU
L9          3007 S E3-E26,E94-E97
                 E BOHRING/PA,CS
L10           10 S E3-E12
                 E BEOHRING/PA,CS
                 E BOEHRING/PA,CS
L11         8534 S BOEHRING?/PA,CS
L12            3 S L1 AND L2-L11
                 SEL RN

     FILE 'REGISTRY' ENTERED AT 08:59:15 ON 14 MAR 2005
L13          347 S E1-E347
L14          151 S L13 AND 46.150.18/RID AND C6-C6/ES AND NC5/ES
L15            8 S L14 AND 4/NR
L16            1 S L15 AND C32H38N4O2
L17            0 S 294849-86-8/CRN
                 E C32H38N4O2/MF
L18            1 S E3 AND 46.150.18/RID AND C6-C6/ES AND NC5/ES
L19            1 S L16,L18

     FILE 'HCAOLD' ENTERED AT 09:02:13 ON 14 MAR 2005
L20            0 S L19

     FILE 'USPATFULL' ENTERED AT 09:02:14 ON 14 MAR 2005
L21            6 S L19

     FILE 'HCAPLUS' ENTERED AT 09:02:35 ON 14 MAR 2005
L22            2 S L19
L23            1 S L22 AND L1-L12
L24            2 S L22,L23

     FILE 'REGISTRY' ENTERED AT 09:03:00 ON 14 MAR 2005

=> fil uspatful
FILE 'USPATFULL' ENTERED AT 09:03:07 ON 14 MAR 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 10 Mar 2005 (20050310/PD)
FILE LAST UPDATED: 10 Mar 2005 (20050310/ED)
HIGHEST GRANTED PATENT NUMBER: US6865747
HIGHEST APPLICATION PUBLICATION NUMBER: US2005055750
CA INDEXING IS CURRENT THROUGH 10 Mar 2005 (20050310/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 10 Mar 2005 (20050310/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2005
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2005

>>>  USPAT2 is now available.  USPATFULL contains full text of the     <<<
>>>  original, i.e., the earliest published granted patents or         <<<
>>>  applications.  USPAT2 contains full text of the latest US         <<<
>>>  publications, starting in 2001, for the inventions covered in     <<<
>>>  USPATFULL.  A USPATFULL record contains not only the original     <<<
>>>  published document but also a list of any subsequent              <<<
>>>  publications.  The publication number, patent kind code, and      <<<
>>>  publication date for all the US publications for an invention     <<<
>>>  are displayed in the PI (Patent Information) field of USPATFULL   <<<
>>>  records and may be searched in standard search fields, e.g., /PN, <<<
>>>  /PK, etc.                                                         <<<
```

>>> USPATFULL and USPAT2 can be accessed and searched together <<<
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<
>>> enter this cluster. <<<
>>> <<<
>>> Use USPATALL when searching terms such as patent assignees, <<<
>>> classifications, or claims, that may potentially change from <<<
>>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d l21 bib abs hitstr tot

L21 ANSWER 1 OF 6 USPATFULL on STN
AN 2004:31819 USPATFULL
TI Aryl ureas with raf kinase and angiogenisis inhibiting activity
IN Dumas, Jacques, Bethany, CT, UNITED STATES
Scott, William J., Guilford, CT, UNITED STATES
Elting, James, Madison, CT, UNITED STATES
Hatoum-Makdad, Holia, Hamden, CT, UNITED STATES
PA BAYER CORPORATION, Pittsburgh, PA (U.S. corporation)
PI US 2004023961 A1 20040205
AI US 2003-361844 A1 20030211 (10)
PRAI US 2002-354948P 20020211 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 46
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4402
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to methods of using aryl ureas to treat diseases mediated by raf kinase and diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **294849-86-8P**
(preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)
RN 294849-86-8 USPATFULL
CN Urea, N-[5-(1,1-dimethylethyl)-2-methylphenyl]-N'-[4-[6-[(3-methoxypropyl)methylamino]-3-pyridinyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

L21 ANSWER 2 OF 6 USPATFULL on STN
AN 2004:25196 USPATFULL
TI Compounds useful as anti-inflammatory agents
IN Cirillo, Pier F., Woodbury, CT, UNITED STATES
Breitfelder, Steffen, Assmannshardt, GERMANY, FEDERAL REPUBLIC OF
Patel, Usha R., Brookfield, CT, UNITED STATES
Proudfoot, John Robert, Newtown, CT, UNITED STATES
Swinamer, Alan D., Bethel, CT, UNITED STATES
Takahashi, Hidenori, LaGrangeville, NY, UNITED STATES
Gilmore, Thomas A., Cambridge, MA, UNITED STATES
Sharma, Rajiv, Foster City, CA, UNITED STATES
PA Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, UNITED STATES, 06877-0368 (U.S. corporation)
PI US 2004019038 A1 20040129
AI US 2003-624289 A1 20030721 (10)
RLI Division of Ser. No. US 2001-962709, filed on 25 Sep 2001, GRANTED, Pat. No. US 6660732 Division of Ser. No. US 2000-505582, filed on 16 Feb 2000, GRANTED, Pat. No. US 6358945
PRAI US 1999-124148P 19990312 (60)
US 1999-165867P 19991116 (60)
DT Utility
FS APPLICATION
LREP BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P O BOX 368, RIDGEFIELD, CT, 06877
CLMN Number of Claims: 22
ECL Exemplary Claim: 1

DRWN No Drawings
LN.CNT 6759
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are novel aromatic compounds which are useful for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are pharmaceutical compositions containing and processes of making such compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **294849-86-8P**
(preparation of aromatic heterocyclic urea antiinflammatory agents by conversion of arylamines to isocyanates followed by addition of heterocyclic amines)
RN 294849-86-8 USPATFULL
CN Urea, N-[5-(1,1-dimethylethyl)-2-methylphenyl]-N'-[4-[6-[(3-methoxypropyl)methylamino]-3-pyridinyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

L21 ANSWER 3 OF 6 USPATFULL on STN
AN 2003:319328 USPATFULL
TI Intermediate arylamine compounds
IN Cirillo, Pier F., Woodbury, CT, UNITED STATES
Breitfelder, Steffen, Ridgefield, CT, UNITED STATES
Patel, Usha R., Brookfield, CT, UNITED STATES
Proudfoot, John R., Newtown, CT, UNITED STATES
Swinamer, Alan D., Danbury, CT, UNITED STATES

PA Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT (U.S. corporation)
PI US 2003225077 A1 20031204
AI US 2003-424613 A1 20030428 (10)
RLI Continuation of Ser. No. US 2001-962057, filed on 25 Sep 2001, PENDING
DT Utility
FS APPLICATION
LREP BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P O BOX 368, RIDGEFIELD, CT, 06877
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5832
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are novel aromatic compounds which are useful for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are and pharmaceutical compositions containing, intermediate compounds and processes of making such compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **294849-86-8P**
(preparation of aromatic heterocyclic urea antiinflammatory agents by conversion of arylamines to isocyanates followed by addition of heterocyclic amines)
RN 294849-86-8 USPATFULL
CN Urea, N-[5-(1,1-dimethylethyl)-2-methylphenyl]-N'-[4-[6-[(3-methoxypropyl)methylamino]-3-pyridinyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

Me

L21 ANSWER 4 OF 6 USPATFULL on STN
AN 2002:157650 USPATFULL
TI Compounds useful as anti-inflammatory agents
IN Betageri, Rajashehar, Bethel, CT, UNITED STATES
Breitfelder, Steffen, Danbury, CT, UNITED STATES
Cirillo, Pier F., Woodbury, CT, UNITED STATES
Gilmore, Thomas A., Middlebury, CT, UNITED STATES
Hickey, Eugene R., Danbury, CT, UNITED STATES
Kirrane, Thomas M., JR., Danbury, CT, UNITED STATES
Moriak, Monica H., Danbury, CT, UNITED STATES
Moss, Neil, Ridgefield, CT, UNITED STATES
Patel, Usha R., Brookfield, CT, UNITED STATES
Proudfoot, John R., Newtown, CT, UNITED STATES
Regan, John R., Larchmont, NY, UNITED STATES
Sharma, Rajiv, Ridgefield, CT, UNITED STATES
Sun, Sanxing, Danbury, CT, UNITED STATES
Swinamer, Alan D., Danbury, CT, UNITED STATES
Takahashi, Hidenori, LaGrangeville, NY, UNITED STATES
PI US 2002082256 A1 20020627
US 6656933 B2 20031202
AI US 2001-962057 A1 20010925 (9)
RLI Division of Ser. No. US 2000-505582, filed on 16 Feb 2000, PENDING
PRAI US 1999-124148P 19990312 (60)
US 1999-165867P 19991116 (60)
DT Utility
FS APPLICATION
LREP BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P O BOX 368, RIDGEFIELD, CT, 06877
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 6137
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are novel aromatic compounds which are useful for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are pharmaceutical compositions containing and processes of making such compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **294849-86-8P**
(preparation of aromatic heterocyclic urea antiinflammatory agents by conversion of arylamines to isocyanates followed by addition of heterocyclic amines)
RN 294849-86-8 USPATFULL
CN Urea, N-[5-(1,1-dimethylethyl)-2-methylphenyl]-N'-[4-[6-[(3-methoxypropyl)methylamino]-3-pyridinyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

L21 ANSWER 5 OF 6 USPATFULL on STN
AN 2002:106298 USPATFULL
TI Compounds useful as anti-inflammatory agents
IN Betageri, Rajashehar, Bethel, CT, UNITED STATES
Breitfelder, Steffen, Danbury, CT, UNITED STATES
Cirillo, Pier F., Woodbury, CT, UNITED STATES
Gilmore, Thomas A., Middlebury, CT, UNITED STATES
Hickey, Eugene R., Danbury, CT, UNITED STATES
Kirrane, Thomas M., Danbury, CT, UNITED STATES
Moriak, Monica H., Danbury, CT, UNITED STATES
Moss, Neil, Ridgefield, CT, UNITED STATES
Patel, Usha R., Brookfield, CT, UNITED STATES
Proudfoot, John R., Newtown, CT, UNITED STATES
Regan, John R., Larchmont, NY, UNITED STATES
Sharma, Rajiv, Ridgefield, CT, UNITED STATES
Sun, Sanxing, Danbury, CT, UNITED STATES
Swinamer, Alan D., Danbury, CT, UNITED STATES
Takahashi, Hidenori, LaGrangeville, NY, UNITED STATES
PI US 2002055507 A1 20020509
US 6660732 B2 20031209
AI US 2001-962709 A1 20010925 (9)
RLI Division of Ser. No. US 2000-505582, filed on 16 Feb 2000, PENDING
PRAI US 1999-124148P 19990312 (60)
US 1999-165867P 19991116 (60)
DT Utility
FS APPLICATION

LREP BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P O BOX 368, RIDGEFIELD, CT, 06877
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 6968
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are novel aromatic compounds which are useful for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are pharmaceutical compositions containing and processes of making such compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **294849-86-8P**
(preparation of aromatic heterocyclic urea antiinflammatory agents by conversion of arylamines to isocyanates followed by addition of heterocyclic amines)
RN 294849-86-8 USPATFULL
CN Urea, N-[5-(1,1-dimethylethyl)-2-methylphenyl]-N'-[4-[6-[(3-methoxypropyl)methylamino]-3-pyridinyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

Me

L21 ANSWER 6 OF 6 USPATFULL on STN
AN 2002:57780 USPATFULL
TI Compounds useful as anti-inflammatory agents
IN Breitfelder, Steffen, Danbury, CT, United States

Cirillo, Pier F., Woodbury, CT, United States
Gilmore, Thomas A., Middlebury, CT, United States
Hickey, Eugene R., Danbury, CT, United States
Proudfoot, John R., Newtown, CT, United States
Regan, John R., Larchmont, NY, United States
Swinamer, Alan D., Danbury, CT, United States
Takahashi, Hidenori, LaGrangeville, NY, United States
PA Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States (U.S. corporation)
PI US 6358945 B1 20020319
AI US 2000-505582 20000216 (9)
PRAI US 1999-124148P 19990312 (60)
US 1999-165867P 19991116 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Raymond, Richard L.
LREP Raymond, Robert P., Bottino, Anthony P., Stempel, Alan R.
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 6875
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are novel aromatic compounds which are useful for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are pharmaceutical compositions containing and processes of making such compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **294849-86-8P**
(preparation of aromatic heterocyclic urea antiinflammatory agents by conversion of arylamines to isocyanates followed by addition of heterocyclic amines)
RN 294849-86-8 USPATFULL
CN Urea, N-[5-(1,1-dimethylethyl)-2-methylphenyl]-N'-[4-[6-[(3-methoxypropyl)methylamino]-3-pyridinyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 09:03:15 ON 14 MAR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 14 Mar 2005 VOL 142 ISS 12
FILE LAST UPDATED: 13 Mar 2005 (20050313/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all hitstr tot l24

L24 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:656575 HCAPLUS
DN 139:197476
ED Entered STN: 22 Aug 2003
TI Preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity
IN Dumas, Jacques; Scott, William J.; Elting, James; Hatoum-Makdad, Holia
PA Bayer Corporation, USA
SO PCT Int. Appl., 142 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-415
ICS A61K031-5355; A61K031-4439; A61K031-4178; A61P035-00; A61P017-06; A61P019-02; A61P027-02; A61P031-06; A61P031-18; A61P031-04
CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003068223	A1	20030821	WO 2003-US4102	20030211
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2004023961	A1	20040205	US 2003-361844	20030211
PRAI US 2002-354948P	P	20020211		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2003068223	ICM	A61K031-415
	ICS	A61K031-5355; A61K031-4439; A61K031-4178; A61P035-00; A61P017-06; A61P019-02; A61P027-02; A61P031-06; A61P031-18; A61P031-04

GI



I

AB 283 Of the title ureas useful for treating diseases mediated by raf kinase and diseases mediated by the VEGF induced signal transduction pathway

characterized by abnormal angiogenesis or hyperpermeability processes, were claimed. Synthesis of 6 ureas such as I was described. Thus, reacting 3-(tert-butyl)-1-(4-methylphenyl)pyrazole-5-ylamine with 4-(2-morpholin-4-ylethoxy)naphthylamine (prepns. given) and CDI in CH2Cl2 afforded 80% I which showed IC50 of < 1 μM in in vitro raf kinase and in in vitro Flk-1 ELISA assay.

ST aryl heterocyclyl urea prepn raf kinase angiogenesis inhibitor; pyrazolyl aryl urea prepn tyrosine kinase Flk1 KDR; antitumor aryl heterocyclyl urea prepn; VEGF induced signal transduction pathway aryl heterocyclyl urea prepn

IT Infection
(Chagas' disease, treatment of; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)

IT Intercalation compounds
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(DNA intercalators; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity for treating hyper-proliferative disorder in combination with addnl. cytotoxic agent or cytostatic chemotherapeutic agent)

IT Toxins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Shiga-like toxin, treatment of effects Shiga-like toxin from E.coli infection; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)

IT Interferons
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-proliferative agent; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity for treating hyper-proliferative disorder in combination with addnl. anti-proliferative agent)

IT Cytotoxic agents
(antimetabolites; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity for treating hyper-proliferative disorder in combination with addnl. cytotoxic agent or cytostatic chemotherapeutic agent)

IT Fertility
(birth control; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)

IT Carcinoma
(bladder, treatment of; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)

IT Skin, disease
(bullous, treatment of bullous disorder associated with subepidermal blister formation; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)

IT Bladder, neoplasm
Head, neoplasm
Lung, neoplasm
Mammary gland, neoplasm
Ovary, neoplasm
Pancreas, neoplasm
Prostate gland, neoplasm
Thyroid gland, neoplasm
(carcinoma, treatment of; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)

IT Intestine, neoplasm
(colon, carcinoma, treatment of; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)

IT Carcinoma
Intestine, neoplasm
(colon, treatment of; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)

IT Eye, disease

(cornea, ulcer, treatment of; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)
IT Ulcer
(corneal, treatment of; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)
IT Thrombosis
(coronary arterial, treatment of coronary thrombosis from atherosclerotic plague; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)
IT Artery, disease
(coronary, thrombosis, treatment of coronary thrombosis from atherosclerotic plague; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)
IT Cartilage, disease
(degeneration, treatment of degenerative cartilage loss following traumatic joint injury; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)
IT Nerve, disease
(demyelination, treatment of; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)
IT Toxins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(enterotoxin A, treatment of effects enterotoxin A from Staphylococcus infection; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)
IT Skin, disease
(epidermolysis bullosa, treatment of dystrophobic epidermolysis bullosa; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)
IT Carcinoma
(head, treatment of; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)
IT Carcinoma
(hepatocellular, treatment of; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)
IT Liver, neoplasm
(hepatoma, treatment of; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)
IT Eye, disease
(macula, degeneration, treatment of age related macular degeneration; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)
IT Carcinoma
(mammary, treatment of; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)
IT Neoplasm
(metastasis, treatment of; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)
IT Microtubule
(microtubule disruptors; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity for treating hyper-proliferative disorder in combination with addnl. cytotoxic agent or cytostatic chemotherapeutic agent)
IT Hematopoietic precursor cell
(myeloid, treatment of myeloid disorder; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)
IT Carcinoma
Neoplasm
(neck, treatment of; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)
IT Neck, anatomical
(neoplasm, carcinoma, treatment of; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)

IT Neck, anatomical
(neoplasm, treatment of; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)
IT Bone, disease
(osteopenia, treatment of osteopenias mediated by MMP activity; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)
IT Carcinoma
(ovarian, treatment of; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)
IT Carcinoma
(pancreatic, treatment of; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)
IT Signal transduction, biological
(preparation of aryl heterocyclyl ureas for treating diseases mediated by the VEGF induced signal transduction pathway)
IT Angiogenesis
Angiogenesis inhibitors
Anti-infective agents
Antiarthritics
Antirheumatic agents
Antitumor agents
Antiviral agents
Contraceptives
Human
Tuberculostatics
(preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)
IT Alkylating agents, biological
(preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity for treating hyper-proliferative disorder in combination with addnl. cytotoxic agent or cytostatic chemotherapeutic agent)
IT Growth factor receptors
Hormone receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity for treating hyper-proliferative disorder in combination with addnl. cytotoxic agent or cytostatic chemotherapeutic agent)
IT Carcinoma
(prostatic, treatment of; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)
IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(proteinuria, treatment of; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)
IT Carcinoma
(pulmonary, treatment of; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)
IT Kidney, neoplasm
(renal cell carcinoma, treatment of; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)
IT Carcinoma
(renal cell, treatment of; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)
IT Eye, disease
(retinal ischemia, treatment of ischemic retinal-vein occlusion; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)
IT Ischemia
(retinal, treatment of ischemic retinal-vein occlusion; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting

activity)
IT Eye, disease
(retinopathy, treatment of; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)
IT Arthritis
(septic, treatment of; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)
IT Neoplasm
(solid, treatment of; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)
IT Disease, animal
(temporomandibular joint, treatment of; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)
IT Joint, anatomical
(temporomandibular, disease, treatment of; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)
IT Carcinoma
(thyroid, treatment of; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)
IT Antiulcer agents
(treatment of corneal ulceration; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)
IT Anticoagulants
(treatment of coronary thrombosis from atherosclerotic plague; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)
IT Helicobacter pylori
(treatment of helicobacter pylori infection during peptic ulcer disease; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)
IT Borrelia burgdorferi
Cytomegalovirus
Human immunodeficiency virus
Influenza virus
Theiler's murine encephalomyelitis virus
Treponema pallidum
(treatment of infection from; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)
IT Neisseria meningitidis
(treatment of meningococcal infection; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)
IT Adenoma
Aneurysm
Head, neoplasm
Infection
Kidney, neoplasm
Leukemia
Lung, neoplasm
Mammary gland, neoplasm
Melanoma
Neuroglia, neoplasm
Osteoarthritis
Ovary, neoplasm
Pancreas, neoplasm
Periodontium, disease
Prostate gland, neoplasm
Psoriasis
Rheumatoid arthritis
Stomach, neoplasm
Tuberculosis
(treatment of; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)
IT Vascular endothelial growth factor receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type VEGFR-2; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)

IT 143180-75-0, DNA topoisomerase I
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(DNA topoisomerase I inhibitors; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity for treating hyper-proliferative disorder in combination with addnl. cytotoxic agent or cytostatic chemotherapeutic agent)

IT 142805-56-9, DNA topoisomerase II
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(DNA topoisomerase II inhibitors; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity for treating hyper-proliferative disorder in combination with addnl. cytotoxic agent)

IT 50-07-7, Mitomycin C 50-18-0, Cyclophosphamide 50-24-8, Prednisolone
50-44-2, 6-Mercaptopurine 50-76-0, Dactinomycin 50-91-9,
5-Fluorodeoxyuridine 51-21-8, 5-Fluorouracil 51-75-2, Mechlorethamine
52-24-4, Thiotepa 53-03-2, Prednisone 53-19-0, Mitotane 55-98-1,
Busulfan 56-53-1, Diethylstilbestrol 57-22-7, Vincristine 57-63-6,
Ethinyl estradiol 57-85-2, Testosterone propionate 58-05-9, Leucovorin
58-96-8, Uridine 59-05-2, Methotrexate 71-58-9,
Medroxyprogesteroneacetate 76-43-7, Fluoxymesterone 125-84-8,
Aminoglutethimide 127-07-1, Hydroxyurea 134-46-3, 5-Fluorodeoxyuridine
monophosphate 147-94-4, Cytarabine 148-82-3, Melphalan 154-42-7,
Thioguanine 154-93-8, Carmustine 305-03-3, Chlorambucil 320-67-2,
5-Azacytidine 446-86-6, Azathioprine 595-33-5, Megestrol acetate
630-56-8, Hydroxyprogesterone caproate 645-05-6, Hexamethylmelamine
671-16-9, Procarbazine 865-21-4, Vinblastine 3778-73-2, Ifosfamide
4291-63-8, Cladribine 4342-03-4, Dacarbazine 9015-68-3, Asparaginase
10540-29-1, Tamoxifen 11056-06-7, Bleomycin 13010-47-4, Lomustine
13311-84-7, Flutamide 13909-09-6, Semustine 15663-27-1, Cisplatin
18378-89-7, Plicamycin 18883-66-4, Streptozocin 19767-45-4, Mesna
20830-81-3, Daunorubicin 23214-92-8, Doxorubicin 29767-20-2,
Teniposide 33069-62-4, Paclitaxel 33419-42-0, Etoposide 41575-94-4,
Carboplatin 51321-79-0 53643-48-4, Vindesine 53910-25-1, Pentostatin
56420-45-2, Epirubicin 58957-92-9, Idarubicin 61825-94-3, Oxaliplatin
65271-80-9, Mitoxantrone 71486-22-1, Vinorelbine 75607-67-9,
Fludarabine phosphate 84449-90-1 95058-81-4, 2',2'-
Difluorodeoxycytidine 97682-44-5, Irinotecan 114977-28-5, Docetaxel
123948-87-8, Topotecan 180288-69-1, Herceptin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-proliferative agent; preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity for treating hyper-proliferative disorder in combination with addnl. anti-proliferative agent)

IT 139691-76-2, Raf kinase 150977-45-0, Flk-1 kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)

IT 223724-90-1P 223725-06-2P 223725-07-3P 223725-08-4P 285983-41-7P
285983-42-8P 285983-43-9P 285983-44-0P 285983-45-1P 285983-47-3P
285983-48-4P 285983-49-5P 285983-50-8P 285983-51-9P 285983-52-0P
285983-54-2P 285983-55-3P 285983-56-4P 285983-57-5P 285983-58-6P
285983-60-0P 285983-61-1P 285983-63-3P 285983-64-4P 285983-66-6P
285983-68-8P 285983-70-2P 285983-74-6P 285983-75-7P 285983-76-8P
285983-77-9P 285983-78-0P 285983-79-1P 285983-89-3P 285983-90-6P
285983-92-8P 285983-93-9P 285983-94-0P 285983-95-1P 285983-96-2P
285983-97-3P 285983-98-4P 285983-99-5P 285984-00-1P 285984-01-2P
285984-02-3P 285984-03-4P 285984-04-5P 285984-05-6P 285984-06-7P
285984-07-8P 285984-08-9P 285984-09-0P 285984-10-3P 285984-11-4P
285984-12-5P 285984-13-6P 285984-14-7P 285984-15-8P 285984-17-0P
285984-18-1P 285984-20-5P 285984-21-6P 294639-45-5P 294639-46-6P

294639-47-7P 294639-49-9P 294639-50-2P 294639-51-3P 294639-52-4P
294639-53-5P 294639-54-6P 294639-55-7P 294639-56-8P 294639-57-9P
294639-58-0P 294639-59-1P 294639-60-4P 294639-61-5P 294639-62-6P
294639-63-7P 294639-64-8P 294639-65-9P 294639-66-0P 294639-67-1P
294639-68-2P 294639-69-3P 294639-70-6P 294639-71-7P 294639-73-9P
294639-74-0P 294639-75-1P 294639-76-2P 294639-77-3P 294639-78-4P
294848-43-4P 294848-46-7P 294848-49-0P 294848-51-4P 294848-53-6P
294848-55-8P 294848-58-1P 294848-61-6P 294848-64-9P 294848-67-2P
294848-70-7P 294848-73-0P 294848-76-3P 294848-79-6P 294848-82-1P
294848-85-4P 294848-88-7P 294848-91-2P 294848-94-5P 294848-96-7P
294848-98-9P 294849-00-6P 294849-02-8P 294849-04-0P 294849-06-2P
294849-08-4P 294849-10-8P 294849-12-0P 294849-16-4P 294849-18-6P
294849-20-0P 294849-22-2P 294849-24-4P 294849-26-6P 294849-28-8P
294849-30-2P 294849-32-4P 294849-34-6P 294849-36-8P 294849-38-0P
294849-40-4P 294849-42-6P 294849-44-8P 294849-46-0P 294849-48-2P
294849-50-6P 294849-52-8P 294849-54-0P 294849-56-2P 294849-58-4P
294849-60-8P 294849-62-0P 294849-64-2P 294849-66-4P 294849-68-6P
294849-72-2P 294849-74-4P 294849-76-6P 294849-78-8P 294849-80-2P
294849-82-4P 294849-84-6P **294849-86-8P** 294849-88-0P
294849-90-4P 294849-92-6P 294849-94-8P 294849-97-1P 294850-00-3P
294850-02-5P 294850-04-7P 294850-06-9P 294850-09-2P 294850-12-7P
294850-15-0P 294850-18-3P 294850-21-8P 294850-24-1P 294850-27-4P
294850-29-6P 294850-31-0P 294850-33-2P 294850-35-4P 294850-37-6P
294850-39-8P 294850-41-2P 294850-43-4P 294850-45-6P 294850-47-8P
294850-49-0P 294850-51-4P 294850-53-6P 294850-55-8P 294850-57-0P
294850-59-2P 294850-61-6P 294850-63-8P 294850-65-0P 294850-67-2P
294850-69-4P 294850-71-8P 294850-73-0P 294850-76-3P 294850-79-6P
294850-81-0P 294850-84-3P 294850-87-6P 294850-90-1P 294850-93-4P
294850-96-7P 294851-02-8P 294851-05-1P 294851-07-3P 294851-09-5P
294851-11-9P 294851-14-2P 294851-16-4P 294851-18-6P 294851-20-0P
294851-22-2P 294851-24-4P 294851-26-6P 294851-28-8P 294851-32-4P
294851-34-6P 294851-36-8P 294851-38-0P 294851-40-4P 294851-42-6P
294851-44-8P 294851-46-0P 294851-48-2P 294851-50-6P 294851-52-8P
294851-56-2P 294851-58-4P 294851-60-8P 294851-62-0P 294851-64-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)

IT 294851-66-4P 294851-68-6P 294851-70-0P 294851-72-2P 294851-74-4P
294851-76-6P 294855-56-4P 340825-40-3P 340825-41-4P 340825-46-9P
340825-47-0P 340825-48-1P 340825-49-2P 340825-51-6P 340825-52-7P
340825-53-8P 340825-54-9P 340825-55-0P 340825-56-1P 340825-57-2P
340825-58-3P 340825-59-4P 477844-71-6P 489432-45-3P 499971-97-0P
501365-69-1P 585531-85-7P 585531-86-8P 585531-87-9P 585531-88-0P
585531-89-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)

IT 368-78-5, 3-Trifluoromethylphenylhydrazine 529-27-1, 2-Methylphenylhydrazine 637-60-5, p-Tolylhydrazine hydrochloride 1822-51-1, 4-Picolyl chloride hydrochloride 3647-69-6, 4-(2-Chloroethyl)morpholine hydrochloride 4900-63-4, 4-Methoxy-1-nitronaphthalene 5959-56-8, 4-Amino-1-naphthol hydrochloride 6498-34-6, Cyclohexylhydrazine 59997-51-2, 4,4-Dimethyl-3-oxopentanenitrile 63693-65-2, 4-Isopropylphenylhydrazine
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)

IT 605-62-9P 285984-22-7P 285984-23-8P 285984-25-0P 317806-88-5P
317806-90-9P 585531-90-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)

RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Bayer Ag; WO 9932106 A 1999 HCAPLUS
(2) Bayer Ag; WO 9932110 A 1999 HCAPLUS
(3) Bayer Ag; WO 9932111 A 1999 HCAPLUS
(4) Bayer Ag; WO 9932455 A 1999 HCAPLUS
(5) Bayer Ag; WO 9932463 A 1999 HCAPLUS
(6) Boehringer Ingelheim Pharma; WO 9923091 A 1999 HCAPLUS
(7) Boehringer Ingelheim Pharma; WO 0043384 A 2000 HCAPLUS
(8) Boehringer Ingelheim Pharma; WO 0055152 A 2000 HCAPLUS
(9) Carl, N; WO 9962890 A 1999 HCAPLUS
(10) Chen, J; WO 9852558 A 1998 HCAPLUS
(11) Cho, T; US 5773459 A 1998 HCAPLUS
(12) Dumas, J; CURRENT OPINION IN DRUG DISCOVERY AND DEVELOPMENT 2002 UNITED KINGDOM 2002, V5(5), P718 HCAPLUS
(13) Ho, H; WO 0136403 A 2001 HCAPLUS
(14) Kubo, K; PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, 93rd Annual Meeting of the American Association for Cancer Research 2002, V43, P182
(15) Madwed, J; IMFLAMMATION RESEARCH 2001, V50(SUPPL 3), PS184
(16) Ple, P; WO 0166099 A 2001 HCAPLUS
(17) Regan; J MED CHEM 2002, V45(14), P2994 HCAPLUS

IT **294849-86-8P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aryl heterocyclyl ureas with raf kinase and angiogenesis inhibiting activity)

RN 294849-86-8 HCAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-2-methylphenyl]-N'-[4-[6-[(3-methoxypropyl)methylamino]-3-pyridinyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

L24 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:666713 HCAPLUS
DN 133:252426
ED Entered STN: 22 Sep 2000
TI Preparation of aromatic heterocyclic ureas as antiinflammatory agents
IN Betageri, Rajashehar; **Breitfelder, Steffen**; **Cirillo, Pier F.**; **Gilmore, Thomas A.**; Hickey, Eugene R.; Kirrane, Thomas M.; Moriak, Monica H.; Moss, Neil; **Patel, Usha R.**; **Proudfoot, John R.**; Regan, John R.; **Sharma, Rajiv**; Sun, Sanxing; **Swinamer, Alan D.**; **Takahashi, Hidenori**
PA **Boehringer Ingelheim Pharmaceuticals, Inc., USA**
SO PCT Int. Appl., 282 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07D231-38
ICS C07D213-38; C07D213-74; A61K031-44; A61K031-50; A61K031-415; A61K031-505; C07D401-14; C07D405-12; C07D401-12; C07D213-76; C07D409-12; C07D493-08; C07D495-08; A61P029-00; C07D493-08; C07D307-00; C07D209-00; C07D495-08; C07D333-00
CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000055139	A2	20000921	WO 2000-US3865	20000216 <--

```
    WO 2000055139          A3    20010426
        W:  AE, AU, BG, BR, BY, CA, CN, CZ, EE, HR, HU, ID, IL, IN, JP, KR,
            KZ, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, UZ, VN,
            YU, ZA
        RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
            PT, SE
    CA 2362003             AA    20000921    CA 2000-2362003        20000216 <--
    EP 1165516             A2    20020102    EP 2000-907295         20000216 <--
    EP 1165516             B1    20041006
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO
    BR 2000008922          A     20020115    BR 2000-8922           20000216 <--
    TR 200102817           T2    20020521    TR 2001-200102817      20000216 <--
    JP 2002539198          T2    20021119    JP 2000-605569         20000216 <--
    EE 200100483           A     20021216    EE 2001-483            20000216 <--
    NZ 514711              A     20040227    NZ 2000-514711         20000216 <--
    AU 771273              B2    20040318    AU 2000-28817          20000216 <--
    EP 1466906             A1    20041013    EP 2004-16841          20000216 <--
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, CY
    AT 278674              E     20041015    AT 2000-907295         20000216 <--
    RU 2242474             C2    20041220    RU 2001-126337         20000216 <--
    BG 105880              A     20020531    BG 2001-105880         20010905 <--
    ZA 2001007446          A     20020910    ZA 2001-7446           20010910 <--
    HR 2001000665          A1    20030630    HR 2001-665            20010910 <--
    NO 2001004412          A     20010911    NO 2001-4412           20010911 <--
    US 2002055507          A1    20020509    US 2001-962709         20010925 <--
    US 6660732             B2    20031209
    US 2002082256          A1    20020627    US 2001-962057         20010925 <--
    US 6656933             B2    20031202
    HK 1043127             A1    20041224    HK 2002-104955         20020702 <--
    US 2003225077          A1    20031204    US 2003-424613         20030428 <--
    US 2004019038          A1    20040129    US 2003-624289         20030721 <--
PRAI US 1999-124148P       P     19990312  <--
    US 1999-165867P        P     19991116  <--
    EP 2000-907295         A3    20000216
    US 2000-505582         A3    20000216  <--
    WO 2000-US3865         W     20000216  <--
    US 2001-962057         A1    20010925  <--
    US 2001-962709         A3    20010925  <--
CLASS
 PATENT NO.        CLASS  PATENT FAMILY CLASSIFICATION CODES
 ----------------  -----  ----------------------------------------------
 WO 2000055139     ICM    C07D231-38
                   ICS    C07D213-38; C07D213-74; A61K031-44; A61K031-50;
                          A61K031-415; A61K031-505; C07D401-14; C07D405-12;
                          C07D401-12; C07D213-76; C07D409-12; C07D493-08;
                          C07D495-08; A61P029-00; C07D493-08; C07D307-00;
                          C07D209-00; C07D495-08; C07D333-00
 EP 1466906        ECLA   C07D213/38; C07D213/74D4; C07D213/76; C07D231/38B3D;
                          C07D401/12+213+209C; C07D401/12+231+213;
                          C07D401/12+241+213; C07D401/12+241B+213;
                          C07D401/14+239B+231+213; C07D405/12+307+213;
                          C07D405/12+307B+231; C07D409/12+335+213;
                          C07D493/08+307B+209B; C07D495/08+333B+209B          <--
 US 2002055507     ECLA   C07D213/38; C07D213/74D4; C07D213/76; C07D231/38B3D;
                          C07D307/12; C07D307/52; C07D401/12+213+29C;
                          C07D401/12+213+211; C07D401/12+231+213;
                          C07D401/12+241B+213; C07D401/12+241+213;
                          C07D401/1+239B+231+213; C07D405/12+307+213;
                          C07D405/12+307B+231; C07D405/12+309+213;
                          C07D409/12+335+213; C07D493/08+307B+209B;
                          C07D495/08+333B+209B                                <--
```

US 2002082256 ECLA C07D213/38; C07D401/12+213+211; C07D401/12+231+213; C07D401/12+241B+213; C07D401/12+241+213; C07D405/12+307+213; C07D405/12+307B+231; C07D405/12+309+213; C07D409/12+35+213; C07D493/08+307B+209B; C07D495/08+333B+209B; C07D213/74D4; C07D213/76; C07D231/38B3D; C07D307/52; C07D401/12+213+209C <--

US 2004019038 ECLA C07D213/38; C07D213/74D4; C07D213/76; C07D231/38B3D; C07D307/12; C07D307/52; C07D401/12+213+29C; C07D401/12+213+211; C07D401/12+231+213; C07D401/12+241B+213; C07D401/12+241+213; C07D401/1+239B+231+213; C07D405/12+307+213; C07D405/12+307B+231; C07D405/12+309+213; C07D409/12+335+213; C07D493/08+307B+209B; C07D495/08+333B+209B <--

OS MARPAT 133:252426

GI



I



II

AB The title compds. (I) [wherein Ar1 = (un)substituted pyrrole, pyrrolidine, pyrazole, imidazole, oxazole, thiazole, furan, or thiophene; Ar2 = (un)substituted Ph, (tetrahydro)naphthyl, (tetrahydro)quinoline, (tetrahydro)isoquinoline, benzimidazole, benzofuran, indanyl, indenyl, or indole; W = O or S; X = (un)substituted cycloalkyl, cycloalkenyl, Ph, furan, thiophene, pyrrole, imidazolyl, pyridine, pyrimidine, (dihydro)pyridinone, (dihydro)maleimide, piperidine, piperazine, or pyrazine; Y = a bond or (un)substituted saturated or unsatd. alkyl optionally interrupted by O, NH, S(O), SO2, or S; Z = (un)substituted Ph, pyridine, pyrimidine, pyridazine, imidazole, (tetrahydro)furan, thiophene, (tetrahydro)pyran, 1,3-dioxolanone, 1,3-dioxanone, 1,4-dioxane, (thio)morpholine (sulfoxide), piperidine, cyclohexanone, pentamethylene sulfoxide, etc.] were prepared for the treatment of diseases or pathol. conditions involving inflammation, such as chronic inflammatory diseases. Thus, coupling 2-cyclohexenone with 4-bromo-1-naphthylamine in the presence of Pd(PPh3)2Cl2, DPPP, and NaHCO3 in DMF, followed by conversion of the amine to an isocyanate using ClCOCl and immediate addition of 1-(4-methylphenyl)-3-tert-butyl-1H-pyrazol-5-amine, gave the urea II. In

a cytokine production inhibition assay, preferred compds. of the invention showed IC50 < 10 μM against TNF-α in lipopolysaccharide stimulated THF cells.

ST arom heterocyclic urea prepn antiinflammatory agent; pyrazolyl arom urea prepn tumor necrosis factor inhibitor; urea arom heterocyclic prepn cytokine inhibitor

IT Anti-inflammatory agents
(preparation of aromatic heterocyclic urea antiinflammatory agents by conversion of arylamines to isocyanates followed by addition of heterocyclic amines)

IT Tumor necrosis factors
RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)
(preparation of aromatic heterocyclic urea antiinflammatory agents by conversion of arylamines to isocyanates followed by addition of heterocyclic amines)

IT 294851-78-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of aromatic heterocyclic urea antiinflammatory agents by conversion of arylamines to isocyanates followed by addition of heterocyclic amines)

IT 294848-43-4P 294848-46-7P 294848-49-0P 294848-51-4P 294848-53-6P
294848-55-8P 294848-58-1P 294848-61-6P 294848-64-9P 294848-67-2P
294848-70-7P 294848-73-0P 294848-76-3P 294848-79-6P 294848-82-1P
294848-85-4P 294848-88-7P 294848-91-2P 294848-94-5P 294848-96-7P
294848-98-9P 294849-00-6P 294849-02-8P 294849-04-0P 294849-06-2P
294849-08-4P 294849-10-8P 294849-12-0P 294849-14-2P 294849-16-4P
294849-18-6P 294849-20-0P 294849-22-2P 294849-24-4P 294849-26-6P
294849-28-8P 294849-30-2P 294849-32-4P 294849-34-6P 294849-36-8P
294849-38-0P 294849-40-4P 294849-42-6P 294849-44-8P 294849-46-0P
294849-48-2P 294849-50-6P 294849-52-8P 294849-54-0P 294849-56-2P
294849-58-4P 294849-60-8P 294849-62-0P 294849-64-2P 294849-66-4P
294849-68-6P 294849-70-0P 294849-72-2P 294849-74-4P 294849-76-6P
294849-78-8P 294849-80-2P 294849-82-4P 294849-84-6P
294849-86-8P 294849-88-0P 294849-90-4P 294849-92-6P
294849-94-8P 294849-97-1P 294850-00-3P 294850-02-5P 294850-04-7P
294850-06-9P 294850-09-2P 294850-12-7P 294850-15-0P 294850-18-3P
294850-21-8P 294850-24-1P 294850-27-4P 294850-29-6P 294850-31-0P
294850-33-2P 294850-35-4P 294850-37-6P 294850-39-8P 294850-41-2P
294850-43-4P 294850-45-6P 294850-47-8P 294850-49-0P 294850-51-4P
294850-53-6P 294850-55-8P 294850-57-0P 294850-59-2P 294850-61-6P
294850-63-8P 294850-65-0P 294850-67-2P 294850-69-4P 294850-71-8P
294850-73-0P 294850-76-3P 294850-79-6P 294850-81-0P 294850-84-3P
294850-87-6P 294850-90-1P 294850-93-4P 294850-96-7P 294850-99-0P
294851-02-8P 294851-05-1P 294851-07-3P 294851-09-5P 294851-11-9P
294851-14-2P 294851-16-4P 294851-18-6P 294851-20-0P 294851-22-2P
294851-24-4P 294851-26-6P 294851-28-8P 294851-30-2P 294851-32-4P
294851-34-6P 294851-36-8P 294851-38-0P 294851-40-4P 294851-42-6P
294851-44-8P 294851-46-0P 294851-48-2P 294851-50-6P 294851-52-8P
294851-54-0P 294851-56-2P 294851-58-4P 294851-60-8P 294851-62-0P
294851-64-2P 294851-66-4P 294851-68-6P 294851-70-0P 294851-72-2P
294851-74-4P 294851-76-6P 294851-79-9P 294851-81-3P 294851-83-5P
294851-85-7P 294851-87-9P 294853-11-5P 294855-56-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aromatic heterocyclic urea antiinflammatory agents by conversion of arylamines to isocyanates followed by addition of heterocyclic amines)

IT 59-48-3, Oxindole 68-12-2, reactions 75-97-8 95-92-1, Diethyloxalate

109-77-3, Malononitrile 110-91-8, Morpholine, reactions 353-07-1, 2-Cyanoethylhydrazine 500-22-1, Pyridine-3-carboxaldehyde 585-34-2, 3-tert-Butylphenol 591-19-5, 3-Bromoaniline 624-28-2, 2,5-Dibromopyridine 626-35-7, Ethyl nitroacetate 628-22-8, 3-Cyano-1-propanol 930-68-7, 2-Cyclohexenone 1072-72-6, Tetrahydro-1,4-thiopyrone 1072-97-5, 2-Amino-5-bromopyridine 1445-73-4, 1-Methyl-4-piperidone 1461-22-9, Tributyltin chloride 1899-24-7, 5-Bromo-2-furaldehyde 2298-07-9, 4-Bromo-1-naphthylamine 3549-23-3, Methyl 4-t-butylphenylacetate 4097-49-8, 4-tert-Butyl-2,6-dinitrophenol 5292-43-3, tert-Butyl bromoacetate 5414-19-7, Bis(2-bromoethyl) ether 6628-77-9, 5-Amino-2-methoxypyridine 7693-46-1, 4-Nitrophenylchloroformate 29943-42-8, Tetrahydro-4-pyranone 35944-64-0, 3-Iodo-4-methylphenylamine 59997-51-2, 4,4-Dimethyl-3-oxopentanenitrile 62559-08-4, 4-tert-Butyl-2-nitrotoluene 89364-31-8, Tetrahydro-3-furoic acid 155959-13-0, 2-tert-Butyl-6-chloro-5-methylpyridine-4-carboxylic acid methyl ester 168169-11-7 285984-25-0 285984-47-6 294853-00-2 294853-07-9 294853-09-1, 5-tert-Butyl-2-methoxyphenylacetic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of aromatic heterocyclic urea antiinflammatory agents by conversion of arylamines to isocyanates followed by addition of heterocyclic amines)

IT 1914-02-9P 4210-60-0P 6309-59-7P 14011-21-3P 16078-32-3P 19155-24-9P 21905-78-2P 21926-00-1P 29682-15-3P 31181-90-5P 32857-63-9P 71897-83-1P 72934-84-0P 79710-86-4P 83405-70-3P 88905-15-1P 99170-18-0P 116584-61-3P 116584-62-4P 160664-95-9P 197846-82-5P 229003-11-6P 261711-84-6P 294851-89-1P 294851-91-5P 294851-93-7P 294851-95-9P 294851-97-1P 294851-99-3P 294852-01-0P 294852-03-2P 294852-05-4P 294852-07-6P 294852-09-8P 294852-12-3P 294852-14-5P 294852-18-9P 294852-20-3P 294852-22-5P 294852-24-7P 294852-26-9P 294852-28-1P 294852-30-5P 294852-32-7P 294852-35-0P 294852-37-2P 294852-39-4P 294852-41-8P 294852-43-0P 294852-45-2P 294852-47-4P 294852-49-6P 294852-50-9P 294852-52-1P 294852-54-3P 294852-59-8P 294852-61-2P 294852-64-5P 294852-66-7P 294852-68-9P 294852-70-3P 294852-71-4P 294852-73-6P 294852-75-8P 294852-76-9P 294852-78-1P 294852-80-5P 294852-82-7P 294852-84-9P 294852-86-1P 294852-88-3P 294852-90-7P 294852-92-9P 294852-94-1P 294852-96-3P 294852-98-5P 294853-13-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aromatic heterocyclic urea antiinflammatory agents by conversion of arylamines to isocyanates followed by addition of heterocyclic amines)

IT **294849-86-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aromatic heterocyclic urea antiinflammatory agents by conversion of arylamines to isocyanates followed by addition of heterocyclic amines)

RN 294849-86-8 HCAPLUS

CN Urea, N-[5-(1,1-dimethylethyl)-2-methylphenyl]-N'-[4-[6-[(3-methoxypropyl)methylamino]-3-pyridinyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

=> => fil reg
FILE 'REGISTRY' ENTERED AT 10:23:42 ON 14 MAR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 13 MAR 2005 HIGHEST RN 845467-46-1
DICTIONARY FILE UPDATES: 13 MAR 2005 HIGHEST RN 845467-46-1

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> d sta que l60

L25 STR



VAR G1=O/S
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 7

STEREO ATTRIBUTES: NONE
L27 SCR 1454 AND 1840 AND 1993
L28 SCR 2039 OR 2050 OR 2049 OR 2048 OR 2053 OR 2052 OR 2051 O
R 2043 OR 2054 OR 1918
L30 9410 SEA FILE=REGISTRY SSS FUL L25 AND L27 NOT L28
L49 STR





VAR G1=O/S
VAR G2=9/14/15/20/21/24/25/30/31
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 8 14 24
NUMBER OF NODES IS 31

STEREO ATTRIBUTES: NONE
L51 8739 SEA FILE=REGISTRY SUB=L30 SSS FUL L49
L57 STR





Cb @34













VAR G1=O/S
VAR G2=34/9/35/39/40/41/42/45/49/48/51/52/53/54/56/61/60/63/62
VAR G3=O/S/N
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS M3-X8 C AT 34

GRAPH ATTRIBUTES:
RSPEC I
NUMBER OF NODES IS 47

STEREO ATTRIBUTES: NONE
L58 STR









VAR G1=O/S

```
VAR G2=68/69/71/73/80/81/75/74/83/84/86/89/91/90/88
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC I
NUMBER OF NODES IS  31

STEREO ATTRIBUTES: NONE
L60         3402 SEA FILE=REGISTRY SUB=L51 SSS FUL (L57 OR L58)

100.0% PROCESSED   8739 ITERATIONS                          3402 ANSWERS
SEARCH TIME: 00.00.01


=> d his

     (FILE 'HOME' ENTERED AT 08:52:21 ON 14 MAR 2005)
               SET COST OFF

     FILE 'HCAPLUS' ENTERED AT 08:52:37 ON 14 MAR 2005
L1             3 S (US20040019038 OR US6660732 OR US20020055507 OR US6656933 OR
               E CIRILLO P/AU
L2            48 S E3,E6-E8
               E BREITFELDER S/AU
L3            19 S E5,E6
               E PATEL U/AU
L4            58 S E3,E12,E37,E41,E42
               E PROUDFOOT J/AU
L5           261 S E3,E5,E7-E9
               E SWINAMER A/AU
L6             9 S E4-E6
               E TAKAHASHI H/AU
L7          1739 S E3-E8,E95-E97
               E GILMORE T/ AU
L8            44 S E3,E4,E11,E12,E21
               E SHARMA R/AU
L9          3007 S E3-E26,E94-E97
               E BOHRING/PA,CS
L10           10 S E3-E12
               E BEOHRING/PA,CS
               E BOEHRING/PA,CS
L11         8534 S BOEHRING?/PA,CS
L12            3 S L1 AND L2-L11
               SEL RN

     FILE 'REGISTRY' ENTERED AT 08:59:15 ON 14 MAR 2005
L13          347 S E1-E347
L14          151 S L13 AND 46.150.18/RID AND C6-C6/ES AND NC5/ES
L15            8 S L14 AND 4/NR
L16            1 S L15 AND C32H38N4O2
L17            0 S 294849-86-8/CRN
               E C32H38N4O2/MF
L18            1 S E3 AND 46.150.18/RID AND C6-C6/ES AND NC5/ES
L19            1 S L16,L18

     FILE 'HCAOLD' ENTERED AT 09:02:13 ON 14 MAR 2005
L20            0 S L19

     FILE 'USPATFULL' ENTERED AT 09:02:14 ON 14 MAR 2005
L21            6 S L19
```

```
     FILE 'HCAPLUS' ENTERED AT 09:02:35 ON 14 MAR 2005
L22            2 S L19
L23            1 S L22 AND L1-L12
L24            2 S L22,L23

     FILE 'REGISTRY' ENTERED AT 09:03:00 ON 14 MAR 2005

     FILE 'USPATFULL' ENTERED AT 09:03:07 ON 14 MAR 2005

     FILE 'HCAPLUS' ENTERED AT 09:03:15 ON 14 MAR 2005

     FILE 'REGISTRY' ENTERED AT 09:03:32 ON 14 MAR 2005
L25              STR
L26            7 S L25
L27              SCR 1454 AND 1840 AND 1993
L28              SCR 2039 OR 2050 OR 2049 OR 2048 OR 2053 OR 2052 OR 2051 OR 204
L29           44 S L25 AND L27 NOT L28 SAM
L30         9410 S L25 AND L27 NOT L28 FUL
                 SAV L30 ZINNA624/A TEMP
L31          103 S C10H8/MF AND C6-C6/ES
L32           48 S L31 NOT (D OR T)/ELS
L33           12 S L32 AND DIHYDRO?
L34            7 S L33 NOT (IUM OR ION)
                 E 591.49/RID
L35          603 S L30 AND E3
                 E TETRAHYDRONAPHTH?/CN
L36            1 S E4
                 E NAPHTHALENE/CN
L37            1 S E3
L38         9352 S 46.150.18/RID AND L30
                 E BENZOCYCLOBUTANE/CN
L39            1 S E3
L40            0 S 191.7/RID AND L30
L41            4 S C4-C6/ES AND L30
                 E BENZOCYCLOHEPTANE/CN
L42            1 S E3
L43            2 S E9
L44            0 S C6-C7/ES AND L30
                 E INDANECN
                 E INDANE/CN
L45            2 S E3
L46           50 S 333.70/RID AND L30
L47           50 S C5-C6/ES AND L30
                 E INDENE/CN
L48            1 S E3
L49              STR L25
L50           50 S L49 SAM SUB=L30
L51         8739 S L49 FUL SUB=L30
                 SAV TEMP L51 ZINNA624A/A
L52          135 S L13 AND L51
L53          134 S L52 NOT L19
L54         8604 S L51 NOT L52
                 E 3H-IMIDAZOL/CN
                 E "3H-IMIDAZO[4,5-B]PYRIDINE"/CN
                 E "3H-IMIDAZO(4,5-B)PYRIDINE"/CN
L55            2 S E3
L56              STR L49
L57              STR L56
L58              STR L56
L59           50 S (L57 OR L58) SAM SUB=L51
L60         3402 S (L57 OR L58) FUL SUB=L51
                 SAV L60 TEMP ZINNA624B/A
```

```
L61          135 S L60 AND L52
L62         3267 S L60 NOT L61
L63          134 S L61 AND L53

     FILE 'HCAOLD' ENTERED AT 09:46:45 ON 14 MAR 2005
L64            0 S L63

     FILE 'HCAPLUS' ENTERED AT 09:47:05 ON 14 MAR 2005
L65            9 S L63
L66            8 S L65 AND L1-L12
L67            2 S L65,L66 AND (PD<=19990312 OR PRD<=19990312 OR AD<=19999312)
L68          576 S L62
L69          444 S L68 AND (PD<=19990312 OR PRD<=19990312 OR AD<=19999312)
                 E INFLAMMATION/CT
L70           20 S E3-E22,E25 AND L69
                 E E3+ALL
L71           19 S E2+NT AND L69
                 E E40+ALL
L72           12 S E4,E5 AND L69
L73           28 S E3,E11-E17 AND L69
L74           43 S L70-L73
L75           38 S L69 AND ?INFLAM?
                 E TUMOR NECROSIS FACTOR/CT
                 E E78+ALL
L76            5 S E3,E4,E2+NT AND L69
                 E E22+ALL
L77            1 S E12-E15,E11+NT AND L69
L78            1 S (TNFALFA OR TNFALPHA OR ALFATNF OR ALPHATNF OR (ALFA OR ALPHA
L79            5 S (TNF OR TUMOR NECROSIS FACTOR) AND L69
L80           44 S L74-L79
L81          211 S L62(L)(THU OR PAC OR PKT OR DMA)/RL
L82           97 S L69 AND L81
L83           31 S L80 AND L82
L84           44 S L80 AND P/DT
L85           42 S L84 AND US/PC,PRC,AC
L86           37 S L84 AND US/PC.B,PRC.B,AC.B
L87           27 S L83 AND L86
L88           17 S L80,L83-L86 NOT L87
L89           44 S L87,L88 AND L68-L88
                 SEL HIT RN

     FILE 'REGISTRY' ENTERED AT 09:56:50 ON 14 MAR 2005
L90          153 S E1-E153
L91            8 S L90 AND (C24H24CL2N2O2 OR C25H28N2O2 OR C24H24F2N2O2 OR C23H2

     FILE 'HCAPLUS' ENTERED AT 10:23:06 ON 14 MAR 2005
L92            2 S L91
L93            4 S L67,L92

     FILE 'REGISTRY' ENTERED AT 10:23:42 ON 14 MAR 2005

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 10:23:59 ON 14 MAR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
```

FILE COVERS 1907 - 14 Mar 2005 VOL 142 ISS 12
FILE LAST UPDATED: 13 Mar 2005 (20050313/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d l92 all hitstr tot

L92 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:433797 HCAPLUS
DN 140:423477
ED Entered STN: 28 May 2004
TI Preparation of diaryl ureas as inhibitors of p38 kinase
IN Miller, Scott; Osterhout, Martin; Dumas, Jacques; Khire, Uday; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Gunn, David E.; Hatoum-Mokdad, Holia; Rodriguez, Marell; Sibley, Robert; Wang, Ming; Turner, Tiffany; Brennan, Catherine
PA Bayer Corporation, USA
SO U.S. Pat. Appl. Publ., 60 pp., Cont. of U.S. Ser. No. 458,015, abandoned.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K031-44
ICS A61K031-381; A61K031-325; A61K031-277; A61K031-17; A61K031-216; A61K031-195
NCL 546306000; 549069000; 558418000; 560024000; 564050000; 564049000; 514349000; 514447000; 514485000; 514522000
CC 25-21 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1, 27, 28, 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004102636	A1	20040527	US 2002-60396	20020201
PRAI US 1997-126439P	P	19971222		
US 1998-285522	B1	19981222		
US 1999-458015	B1	19991210		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2004102636	ICM	A61K031-44
	ICS	A61K031-381; A61K031-325; A61K031-277; A61K031-17; A61K031-216; A61K031-195
	NCL	546306000; 549069000; 558418000; 560024000; 564050000; 564049000; 514349000; 514447000; 514485000; 514522000

OS MARPAT 140:423477
AB A method of treating a p-38 mediated disease other than cancer comprises administration of BNHCONHA [A = (substituted) Ph, pyridyl, 2-thienyl; B = (substituted) aryl, heteroaryl containing ≥1 6-membered aromatic structure containing 0-4 N, O, or S atoms]. Thus, 5-tert-butyl-2-(3-tetrahydrofuranyloxy)aniline (preparation given) and p-tolyl isocyanate were stirred 8 h in PhMe to give 75% N-(5-tert-butyl-2-(3-tetrahydrofuranyloxy)phenyl)-N'-(4-methylphenyl)urea. Title compds. inhibited p38 kinase with IC50 = 1-10 μM.
ST urea diaryl prepn p38 protein kinase inhibitor
IT Transplant and Transplantation
(host-vs.-graft reaction; preparation of diaryl ureas as inhibitors for treating diseases mediated by a cytokine or protease regulated by p38)

IT Intestine, disease
(inflammatory; preparation of diaryl ureas as inhibitors for treating diseases mediated by a cytokine or protease regulated by p38)
IT Anti-inflammatory agents
Antiarthritics
Antiasthmatics
Antirheumatic agents
Asthma
Human
Immunity
Immunomodulators
Inflammation
Osteoarthritis
Osteoporosis
Rheumatoid arthritis
(preparation of diaryl ureas as inhibitors for treating diseases mediated by a cytokine or protease regulated by p38)
IT Interleukin 1
Interleukin 6
Interleukin 8
Tumor necrosis factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of diaryl ureas as inhibitors for treating diseases mediated by a cytokine or protease regulated by p38)
IT Shock (circulatory collapse)
(septic; preparation of diaryl ureas as inhibitors for treating diseases mediated by a cytokine or protease regulated by p38)
IT 165245-96-5, p38 Kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; preparation of diaryl ureas as inhibitors of p38 kinase)
IT 9001-12-1, MMP-1 79955-99-0, MMP-3
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of diaryl ureas as inhibitors for treating diseases mediated by a cytokine or protease regulated by p38)
IT 228416-78-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of diaryl ureas as inhibitors of p38 kinase)
IT 370-50-3P 117745-34-3P 228399-32-4P 228399-33-5P 228399-34-6P
228399-35-7P 228399-38-0P 228399-41-5P 228399-44-8P 228399-45-9P
228399-61-9P 228399-62-0P 228399-63-1P 228399-65-3P 228399-66-4P
228399-68-6P 228399-69-7P 228399-70-0P 228399-71-1P 228399-72-2P
228399-74-4P 228399-82-4P 228399-84-6P 228400-63-3P 228400-64-4P
228400-65-5P 228400-87-1P 228400-92-8P 228400-93-9P 228400-94-0P
228400-95-1P 228400-96-2P 228400-97-3P 228400-99-5P 228401-00-1P
228401-01-2P 228401-02-3P 228401-03-4P 228401-04-5P 228401-06-7P
228401-07-8P 228416-61-3P 228416-62-4P 228416-63-5P 228416-64-6P
228416-65-7P 228416-66-8P 228416-67-9P 228416-68-0P 228416-69-1P
228416-70-4P 228416-71-5P 228416-72-6P 228416-73-7P 228416-74-8P
228416-75-9P 228416-76-0P 228416-79-3P 228416-81-7P 228416-83-9P
228416-85-1P 228416-87-3P 228416-89-5P 228416-91-9P 228416-93-1P
228416-96-4P 228416-99-7P 228417-03-6P 228417-06-9P 228417-09-2P
228417-12-7P 228417-14-9P 228417-18-3P 228417-21-8P 228417-24-1P
228417-27-4P 228417-30-9P 228417-33-2P 228417-36-5P 228417-38-7P
228417-40-1P 228417-42-3P 228417-44-5P 228417-46-7P 228417-48-9P
228417-50-3P 228417-52-5P 228417-53-6P 228417-54-7P 228417-55-8P
228417-56-9P 228417-57-0P 228417-58-1P 228417-59-2P
228417-60-5P 228417-61-6P **228417-62-7P**
228417-63-8P 228417-64-9P 228417-65-0P
228417-66-1P 228417-67-2P 228417-68-3P
228417-69-4P 228417-70-7P 228417-71-8P 228417-72-9P 228417-74-1P
228417-76-3P 228417-78-5P 228417-79-6P 228417-80-9P 228417-81-0P

228417-82-1P 228417-83-2P 228417-84-3P 228417-85-4P 228417-86-5P
228417-87-6P 228417-88-7P 228417-89-8P 228417-90-1P 228417-91-2P
228417-92-3P 228417-93-4P 228417-94-5P 228417-95-6P 228417-96-7P
228417-97-8P 228417-98-9P 228417-99-0P 228418-00-6P 228418-01-7P
228418-02-8P 228418-03-9P 228418-04-0P 228418-05-1P 228418-06-2P
228418-07-3P 228418-08-4P 228418-09-5P 228418-11-9P 228418-12-0P
228418-13-1P 228418-14-2P 228418-15-3P 228418-16-4P 228418-17-5P
228418-18-6P 228418-19-7P 228418-20-0P 228418-21-1P 228418-22-2P
228418-23-3P 228418-24-4P 228418-25-5P 228418-26-6P 228418-27-7P
228418-28-8P 228418-31-3P 228418-32-4P 228418-33-5P 228418-36-8P
228418-37-9P 228418-38-0P 228418-39-1P 228418-40-4P 228418-41-5P
228418-42-6P 228418-48-2P 228418-49-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of diaryl ureas as inhibitors of p38 kinase)

IT 86-84-0, 1-Naphthyl isocyanate 96-49-1, Ethylene carbonate 100-11-8, 4-Nitrobenzyl bromide 100-15-2, N-Methyl-4-nitroaniline 101-77-9 106-44-5, reactions 106-49-0, p-Toluidine, reactions 108-30-5, reactions 109-00-2, 3-Hydroxypyridine 110-91-8, Morpholine, reactions 123-30-8, 4-Aminophenol 150-76-5, 4-Methoxyphenol 288-32-4, Imidazole, reactions 320-94-5, 2-Nitro-4-trifluoromethylbenzoic acid 327-78-6 349-65-5, 2-Methoxy-5-trifluoromethylaniline 350-46-9, 1-Fluoro-4-nitrobenzene 371-40-4, 4-Fluoroaniline 400-74-8, 2-Fluoro-5-nitrobenzotrifluoride 452-80-2, 2-Fluoro-4-methylaniline 453-20-3, 3-Hydroxytetrahydrofuran 498-74-8 542-69-8, 1-Iodobutane 551-06-4, 1-Naphthyl isothiocyanate 585-34-2, m-tert-Butylphenol 585-79-5, 1-Bromo-3-nitrobenzene 598-21-0, Bromoacetyl bromide 620-95-1, 3-Benzylpyridine 622-58-2, p-Tolyl isocyanate 624-28-2, 2,5-Dibromopyridine 626-61-9, 4-Chloropyridine 673-09-6 768-35-4 872-31-1, 3-Bromothiophene 883-99-8, Methyl 3-hydroxy-2-naphthoate 1083-48-3, 4-(4-Nitrobenzyl)pyridine 1121-78-4, 5-Hydroxy-2-methylpyridine 1849-36-1 2033-89-8, 3,4-Dimethoxyphenol 2103-88-0, 2-Mercapto-4-phenylthiazole 3279-07-0, 4-tert-Butyl-2-nitrophenol 3535-88-4, 5-tert-Butyl-2-methoxyaniline 3678-63-5 4548-45-2, 2-Chloro-5-nitropyridine 4556-23-4, 4-Mercaptopyridine 4595-59-9, 5-Bromopyrimidine 6310-19-6, 4-tert-Butyl-2-nitroaniline 6358-07-2 7379-35-3, 4-Chloropyridine hydrochloride 21101-60-0, 4-(4-Nitrophenylthio)phenol 22948-02-3, 3-Aminothiophenol 29264-35-5 36265-31-3 59669-59-9, 5-Amino-3-tert-butylisoxazole 73322-01-7 198077-72-4 228401-47-6 228401-48-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of diaryl ureas as inhibitors of p38 kinase)

IT 726-17-0P 780-90-5P 843-06-1P 883-62-5P 885-87-0P 5651-77-4P 6337-24-2P 13041-60-6P 13472-85-0P 16588-75-3P 18994-90-6P 27692-74-6P 28232-34-0P 28232-52-2P 31465-36-8P 32361-76-5P 36089-89-1P 40299-87-4P 51834-97-0P 61500-87-6P 62248-47-9P 62248-51-5P 64064-63-7P 67291-63-8P 70991-08-1P 92575-23-0P 116289-71-5P 135680-03-4P 142596-52-9P 178809-75-1P 220000-87-3P 228401-08-9P 228401-09-0P 228401-10-3P 228401-11-4P 228401-14-7P 228401-15-8P 228401-16-9P 228401-17-0P 228401-18-1P 228401-19-2P 228401-20-5P 228401-21-6P 228401-23-8P 228401-24-9P 228401-26-1P 228401-27-2P 228401-28-3P 228401-29-4P 228401-31-8P 228401-32-9P 228401-33-0P 228401-34-1P 228401-35-2P 228401-36-3P 228401-37-4P 228401-38-5P 228401-39-6P 228401-40-9P 228401-41-0P 228401-43-2P 228401-44-3P 228401-45-4P 228418-45-9P 228418-46-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of diaryl ureas as inhibitors of p38 kinase)

IT **228417-60-5P 228417-62-7P 228417-63-8P**
228417-64-9P 228417-65-0P 228417-66-1P
228417-67-2P 228417-68-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of diaryl ureas as inhibitors of p38 kinase)

RN 228417-60-5 HCAPLUS

CN Urea, N-[4-(1,1-dimethylethyl)-3'-methoxy[1,1'-biphenyl]-2-yl]-N'-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 228417-62-7 HCAPLUS

CN Urea, N-(2,3-dichlorophenyl)-N'-[4-(1,1-dimethylethyl)-3'-methoxy[1,1'-biphenyl]-2-yl]- (9CI) (CA INDEX NAME)



RN 228417-63-8 HCAPLUS

CN Urea, N-(2,4-difluorophenyl)-N'-[4-(1,1-dimethylethyl)-3'-methoxy[1,1'-biphenyl]-2-yl]- (9CI) (CA INDEX NAME)



RN 228417-64-9 HCAPLUS

CN Urea, N-[4-(1,1-dimethylethyl)-3'-fluoro[1,1'-biphenyl]-2-yl]-N'-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 228417-65-0 HCAPLUS
CN Urea, N-[4-(1,1-dimethylethyl)-4'-fluoro[1,1'-biphenyl]-2-yl]-N'-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 228417-66-1 HCAPLUS
CN Urea, N-[4-(1,1-dimethylethyl)-4'-fluoro[1,1'-biphenyl]-2-yl]-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 228417-67-2 HCAPLUS
CN Urea, N-(2,3-dichlorophenyl)-N'-[4-(1,1-dimethylethyl)-4'-fluoro[1,1'-biphenyl]-2-yl]- (9CI) (CA INDEX NAME)



RN 228417-68-3 HCAPLUS
CN Urea, N-(2,4-difluorophenyl)-N'-[4-(1,1-dimethylethyl)-4'-fluoro[1,1'-biphenyl]-2-yl]- (9CI) (CA INDEX NAME)



L92 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:421667 HCAPLUS
DN 131:58659
ED Entered STN: 08 Jul 1999
TI Preparation of diaryl ureas as inhibitors of p38 kinase.
IN Miller, Scott; Osterhout, Martin; Dumas, Jacques; Khire, Uday; Lowinger, Timothy Bruno; Riedl, Bernd; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Gunn, David; Hatoum-Mokdad, Holia; Rodriguez, Mareli; Sibley, Robert; Wang, Ming
PA Bayer Corporation, USA
SO PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07D273-00
ICS C07D275-00; A61K031-17
CC 25-21 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1, 27, 28
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9932463	A1	19990701	WO 1998-US27265	19981222
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2315715	AA	19990701	CA 1998-2315715	19981222

AU 9919399 A1 19990712 AU 1999-19399 19981222
EP 1042305 A1 20001011 EP 1998-964221 19981222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
JP 2001526276 T2 20011218 JP 2000-525400 19981222
PRAI US 1997-995749 A 19971222
WO 1998-US27265 W 19981222

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9932463	ICM	C07D273-00
	ICS	C07D275-00; A61K031-17
WO 9932463	ECLA	A61K031/17; A61K031/4402; A61K031/4406; A61K031/4409; A61K031/4436; A61K031/4439; A61K031/535P; C07C275/30; C07C275/34; C07C275/36; C07C309/88; C07C311/48; C07C317/42; C07D207/26B2; C07D207/26C; C07D207/26L; C07D207/40B; C07D209/76; C07D209/88; C07D213/40L; C07D213/53B; C07D213/70D; C07D231/08; C07D233/22; C07D233/70; C07D277/68B; C07D307/20; C07D333/0; C07D409/12+333B+213; A61K031/403; A61K031/4035; A61K031/428; A61K031/44+A

OS MARPAT 131:58659

AB A method of treating a p-38 mediated disease other than cancer comprises administration of BNHCONHA [A = (substituted) Ph, pyridyl, 2-thienyl; B = (substituted) aryl, heteroaryl containing ≥1 6-membered aromatic structure containing 0-4 N, O, or S atoms]. Thus, 5-tert-butyl-2-(3-tetrahydrofuranyloxy)aniline (preparation given) and p-tolyl isocyanate were stirred 8 h in PhMe to give 75% N-(5-tert-butyl-2-(3-tetrahydrofuranyloxy)phenyl)-N'-(4-methylphenyl)urea. Title compds. inhibited p38 kinase with IC50 = 1-10 μM.

ST urea diaryl prepn protein kinase inhibitor

IT 165245-96-5, p38 Kinase
RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)
(inhibitors; preparation of diaryl ureas as inhibitors of p38 kinase)

IT 228416-78-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of diaryl ureas as inhibitors of p38 kinase)

IT 370-50-3P 117745-34-3P 228399-32-4P 228399-33-5P 228399-34-6P
228399-35-7P 228399-38-0P 228399-44-8P 228399-45-9P 228399-61-9P
228399-62-0P 228399-63-1P 228399-65-3P 228399-66-4P 228399-68-6P
228399-69-7P 228399-70-0P 228399-71-1P 228399-72-2P 228399-74-4P
228399-82-4P 228399-84-6P 228400-63-3P 228400-64-4P 228400-65-5P
228400-87-1P 228400-92-8P 228400-93-9P 228400-94-0P 228400-95-1P
228400-96-2P 228400-97-3P 228400-99-5P 228401-00-1P 228401-01-2P
228401-02-3P 228401-03-4P 228401-04-5P 228401-06-7P 228401-07-8P
228416-61-3P 228416-62-4P 228416-63-5P 228416-64-6P 228416-65-7P
228416-66-8P 228416-67-9P 228416-68-0P 228416-69-1P 228416-70-4P
228416-71-5P 228416-72-6P 228416-73-7P 228416-74-8P 228416-75-9P
228416-76-0P 228416-79-3P 228416-81-7P 228416-83-9P 228416-85-1P
228416-87-3P 228416-89-5P 228416-91-9P 228416-93-1P 228416-96-4P
228416-99-7P 228417-03-6P 228417-06-9P 228417-09-2P 228417-12-7P
228417-14-9P 228417-18-3P 228417-21-8P 228417-24-1P 228417-27-4P
228417-30-9P 228417-33-2P 228417-36-5P 228417-38-7P 228417-40-1P
228417-42-3P 228417-44-5P 228417-46-7P 228417-48-9P 228417-50-3P
228417-52-5P 228417-53-6P 228417-54-7P 228417-55-8P 228417-56-9P
228417-57-0P 228417-58-1P 228417-59-2P **228417-60-5P**
228417-61-6P **228417-62-7P** **228417-63-8P**
228417-64-9P **228417-65-0P** **228417-66-1P**
228417-67-2P **228417-68-3P** 228417-69-4P 228417-70-7P

228417-71-8P 228417-72-9P 228417-74-1P 228417-76-3P 228417-78-5P
228417-79-6P 228417-80-9P 228417-81-0P 228417-82-1P 228417-83-2P
228417-84-3P 228417-85-4P 228417-86-5P 228417-87-6P 228417-88-7P
228417-89-8P 228417-90-1P 228417-91-2P 228417-92-3P 228417-93-4P
228417-94-5P 228417-95-6P 228417-96-7P 228417-97-8P 228417-98-9P
228417-99-0P 228418-00-6P 228418-01-7P 228418-02-8P 228418-03-9P
228418-04-0P 228418-05-1P 228418-06-2P 228418-07-3P 228418-08-4P
228418-09-5P 228418-11-9P 228418-12-0P 228418-13-1P 228418-14-2P
228418-15-3P 228418-16-4P 228418-17-5P 228418-18-6P 228418-19-7P
228418-20-0P 228418-21-1P 228418-22-2P 228418-23-3P 228418-24-4P
228418-25-5P 228418-26-6P 228418-27-7P 228418-28-8P 228418-31-3P
228418-32-4P 228418-33-5P 228418-36-8P 228418-37-9P 228418-38-0P
228418-39-1P 228418-40-4P 228418-41-5P 228418-42-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of diaryl ureas as inhibitors of p38 kinase)

IT 228399-41-5 228418-48-2 228418-49-3
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of diaryl ureas as inhibitors of p38 kinase)

IT 86-84-0, 1-Naphthyl isocyanate 96-49-1, Ethylene carbonate 100-11-8, 4-Nitrobenzyl bromide 100-15-2, N-Methyl-4-nitroaniline 101-77-9 106-44-5, reactions 106-49-0, p-Toluidine, reactions 108-30-5, reactions 109-00-2, 3-Hydroxypyridine 110-91-8, Morpholine, reactions 123-30-8, 4-Aminophenol 150-76-5, 4-Methoxyphenol 288-32-4, Imidazole, reactions 320-94-5, 2-Nitro-4-trifluoromethylbenzoic acid 327-78-6 349-65-5, 2-Methoxy-5-trifluoromethylaniline 350-46-9, 1-Fluoro-4-nitrobenzene 371-40-4, 4-Fluoroaniline 400-74-8, 2-Fluoro-5-nitrobenzotrifluoride 452-80-2, 2-Fluoro-4-methylaniline 453-20-3, 3-Hydroxytetrahydrofuran 498-74-8 542-69-8, 1-Iodobutane 551-06-4, 1-Naphthyl isothiocyanate 585-34-2, m-tert-Butylphenol 585-79-5, 1-Bromo-3-nitrobenzene 598-21-0, Bromoacetyl bromide 620-95-1, 3-Benzylpyridine 622-58-2, p-Tolyl isocyanate 624-28-2, 2,5-Dibromopyridine 626-61-9, 4-Chloropyridine 673-09-6 768-35-4 872-31-1, 3-Bromothiophene 883-99-8, Methyl 3-hydroxy-2-naphthoate 1083-48-3, 4-(4-Nitrobenzyl)pyridine 1121-78-4, 5-Hydroxy-2-methylpyridine 1849-36-1 2033-89-8, 3,4-Dimethoxyphenol 2103-88-0, 2-Mercapto-4-phenylthiazole 3279-07-0, 4-tert-Butyl-2-nitrophenol 3535-88-4, 5-tert-Butyl-2-methoxyaniline 3678-63-5 4548-45-2, 2-Chloro-5-nitropyridine 4556-23-4, 4-Mercaptopyridine 4595-59-9, 5-Bromopyrimidine 6310-19-6, 4-tert-Butyl-2-nitroaniline 6358-07-2 7379-35-3, 4-Chloropyridine hydrochloride 21101-60-0, 4-(4-Nitrophenylthio)phenol 22948-02-3, 3-Aminothiophenol 29264-35-5 36265-31-3 59669-59-9, 5-Amino-3-tert-butylisoxazole 73322-01-7 198077-72-4 228401-47-6 228401-48-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of diaryl ureas as inhibitors of p38 kinase)

IT 726-17-0P 780-90-5P 843-06-1P 883-62-5P 885-87-0P 5651-77-4P 6337-24-2P 13041-60-6P 13472-85-0P 16588-75-3P 18994-90-6P 27692-74-6P 28232-34-0P 28232-52-2P 31465-36-8P 32361-76-5P 36089-89-1P 40299-87-4P 51834-97-0P 61500-87-6P 62248-47-9P 62248-51-5P 64064-63-7P 67291-63-8P 70991-08-1P 92575-23-0P 116289-71-5P 135680-03-4P 142596-52-9P 178809-75-1P 220000-87-3P 228401-08-9P 228401-09-0P 228401-10-3P 228401-11-4P 228401-14-7P 228401-15-8P 228401-16-9P 228401-17-0P 228401-18-1P 228401-19-2P 228401-20-5P 228401-21-6P 228401-23-8P 228401-24-9P 228401-26-1P 228401-27-2P 228401-28-3P 228401-29-4P 228401-31-8P 228401-32-9P 228401-33-0P 228401-34-1P 228401-35-2P 228401-36-3P 228401-37-4P 228401-38-5P 228401-39-6P 228401-40-9P 228401-41-0P 228401-43-2P 228401-44-3P 228401-45-4P 228418-45-9P 228418-46-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(preparation of diaryl ureas as inhibitors of p38 kinase)
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Frick; US 3230141 1966
(2) Geigy, J; GB 0828231 A 1960 HCAPLUS
(3) Kabbe; US 4405644 A 1983 HCAPLUS
(4) Martin; US 3151023 A 1964
(5) Martin; US 3200035 A 1965
IT **228417-60-5P 228417-62-7P 228417-63-8P**
228417-64-9P 228417-65-0P 228417-66-1P
228417-67-2P 228417-68-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of diaryl ureas as inhibitors of p38 kinase)
RN 228417-60-5 HCAPLUS
CN Urea, N-[4-(1,1-dimethylethyl)-3'-methoxy[1,1'-biphenyl]-2-yl]-N'-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 228417-62-7 HCAPLUS
CN Urea, N-(2,3-dichlorophenyl)-N'-[4-(1,1-dimethylethyl)-3'-methoxy[1,1'-biphenyl]-2-yl]- (9CI) (CA INDEX NAME)



RN 228417-63-8 HCAPLUS
CN Urea, N-(2,4-difluorophenyl)-N'-[4-(1,1-dimethylethyl)-3'-methoxy[1,1'-biphenyl]-2-yl]- (9CI) (CA INDEX NAME)



RN 228417-64-9 HCAPLUS
CN Urea, N-[4-(1,1-dimethylethyl)-3'-fluoro[1,1'-biphenyl]-2-yl]-N'-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 228417-65-0 HCAPLUS
CN Urea, N-[4-(1,1-dimethylethyl)-4'-fluoro[1,1'-biphenyl]-2-yl]-N'-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 228417-66-1 HCAPLUS
CN Urea, N-[4-(1,1-dimethylethyl)-4'-fluoro[1,1'-biphenyl]-2-yl]-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 228417-67-2 HCAPLUS
CN Urea, N-(2,3-dichlorophenyl)-N'-[4-(1,1-dimethylethyl)-4'-fluoro[1,1'-biphenyl]-2-yl]- (9CI) (CA INDEX NAME)



RN 228417-68-3 HCAPLUS
CN Urea, N-(2,4-difluorophenyl)-N'-[4-(1,1-dimethylethyl)-4'-fluoro[1,1'-biphenyl]-2-yl]- (9CI) (CA INDEX NAME)



=> d l67 all fhitstr tot

L67 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:185696 HCAPLUS
DN 136:247592
ED Entered STN: 15 Mar 2002
TI Preparation of heterocyclyl arylamides and ureas as antiinflammatory agents
IN **Breitfelder, Steffen; Cirillo, Pier F.**; Regan, John R.
PA Germany
SO U.S. Pat. Appl. Publ., 36 pp., Cont.-in-part of U.S. Ser. No. 505,582.
CODEN: USXXCO

DT Patent
LA English
IC ICM A61K031-5377
ICS C07D413-02
NCL 514227800
CC 28-13 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 2002032195	A1	20020314	US 2001-834797	20010413	<--
	US 6608052	B2	20030819			
	US 6358945	B1	20020319	US 2000-505582	20000216	<--
	US 2002055507	A1	20020509	US 2001-962709	20010925	<--
	US 6660732	B2	20031209			
	US 2002082256	A1	20020627	US 2001-962057	20010925	<--
	US 6656933	B2	20031202			
	US 2003065034	A1	20030403	US 2002-264689	20021004	<--
	US 6703525	B2	20040309			
	US 2003225077	A1	20031204	US 2003-424613	20030428	<--
	US 2004019038	A1	20040129	US 2003-624289	20030721	<--
PRAI	US 2000-505582	A2	20000216	<--		
	US 1999-124148P	P	19990312	<--		
	US 1999-165867P	P	19991116	<--		
	US 2001-834797	A2	20010413			
	US 2001-962057	A1	20010925	<--		
	US 2001-962709	A3	20010925	<--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2002032195	ICM	A61K031-5377
	ICS	C07D413-02
	NCL	514227800
US 2002032195	ECLA	C07D213/38; C07D307/12; C07D307/52; C07D401/12+213+211; C07D405/12+309+213; C07D409/12+335+213 <--
US 6358945	ECLA	C07D213/38; C07D213/74D4; C07D213/76; C07D231/38B3D; C07D307/12; C07D307/52; C07D401/12+213+29C; C07D401/12+213+211; C07D401/12+231+213; C07D401/12+241B+213; C07D401/12+241+213; C07D401/1+239B+231+213; C07D405/12+307+213; C07D405/12+307B+231; C07D405/12+309+213; C07D409/12+335+213; C07D493/08+307B+209B; C07D495/08+333B+209B <--
US 2002055507	ECLA	C07D213/38; C07D213/74D4; C07D213/76; C07D231/38B3D; C07D307/12; C07D307/52; C07D401/12+213+29C; C07D401/12+213+211; C07D401/12+231+213; C07D401/12+241B+213; C07D401/12+241+213; C07D401/1+239B+231+213; C07D405/12+307+213; C07D405/12+307B+231; C07D405/12+309+213; C07D409/12+335+213; C07D493/08+307B+209B; C07D495/08+333B+209B <--
US 2002082256	ECLA	C07D213/38; C07D401/12+213+211; C07D401/12+231+213; C07D401/12+241B+213; C07D401/12+241+213; C07D405/12+307+213; C07D405/12+307B+231; C07D405/12+309+213; C07D409/12+35+213; C07D493/08+307B+209B; C07D495/08+333B+209B; C07D213/74D4; C07D213/76; C07D231/38B3D; C07D307/52; C07D401/12+213+209C <--
US 2003065034	ECLA	C07D213/38; C07D307/12; C07D307/52; C07D401/12+213+211; C07D405/12+309+213; C07D409/12+335+213 <--
US 2004019038	ECLA	C07D213/38; C07D213/74D4; C07D213/76; C07D231/38B3D; C07D307/12; C07D307/52; C07D401/12+213+29C; C07D401/12+213+211; C07D401/12+231+213;

C07D401/12+241B+213; C07D401/12+241+213;
C07D401/1+239B+231+213; C07D405/12+307+213;
C07D405/12+307B+231; C07D405/12+309+213;
C07D409/12+335+213; C07D493/08+307B+209B;
C07D495/08+333B+209B <--

OS MARPAT 136:247592

AB GEC(:W)NHArXYZ [E = O, NH, S; G = (substituted) Ph, naphthyl, benzocyclobutyl, dihydronaphthyl, benzocycloheptyl, indanyl, indenyl, pyridyl, quinolinyl, oxetanyl, pyrrolidinyl, piperidinyl, etc.; Ar = (substituted) Ph, naphthyl, quinolinyl, isoquinolinyl, tetrahydronaphthyl, benzofuryl, benzothienyl, benzimidazolyl, indanyl, etc.; X = (substituted) cycloalkyl, cycloalkenyl, aryl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, pyridinyl, etc.; Y = bond, (substituted) (O-, S-, SO-, SO2-, N-interrupted) alkylene; Z = (substituted) pyridinyl, piperazinyl, pyrimidinyl, pyrazinyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furyl, thienyl, etc.; W = O, S], were prepared Thus, 5-tert-butyl-2-methoxy-1,3-dinitrobenzene (preparation given) was stirred with ammonium formate and Pd/C in EtOH followed by 3 h reflux to give 90% diamine, which in MeOH was treated with 3,4-dimethoxycyclobutene-1,2-dione at 0-5° followed by stirring and warming to room temperature to give an intermediate. The intermediate in THF was treated with Me2NH at 0-5° followed by stirring and warming to room temperature to give the dimethylamino intermediate.

The latter in CH2Cl2 was treated with COCl2 in PhMe and aqueous NaHCO3 followed by removal of most volatiles. The residue was added to 1-amino-4-(6-morpholin-4-ylmethylpyridin-3-yl)naphthalene (preparation given) in THF followed by stirring overnight to give 1-[5-tert-butyl-3-(2-dimethylamino-3,4-dioxocyclobut-1-enylamino)-2-methoxyphenyl]-3-[4-(6-morpholin-4-ylmethylpyridin-3-yl)naphthalen-1-yl]urea. Preferred title compds. inhibited TNFα production in THP cells with IC50<10 μM.

ST heterocyclyl arylamide urea prepn antiinflammatory; tumor necrosis factor prodn inhibitor heterocyclyl arylurea prepn; cytokine mediated disease treatment heterocyclyl arylurea; dioxocyclobutenylaminomethoxyphenylmorpho linylmethylpyridinylnaphthalenylurea prepn drug

IT Inflammation
(Crohn's disease, treatment; preparation of heterocyclyl arylamides and ureas as antiinflammatory agents)

IT Intestine, disease
(Crohn's, treatment; preparation of heterocyclyl arylamides and ureas as antiinflammatory agents)

IT Nervous system, disease
(Guillain-Barre syndrome, treatment; preparation of heterocyclyl arylamides and ureas as antiinflammatory agents)

IT Respiratory distress syndrome
(adult, treatment; preparation of heterocyclyl arylamides and ureas as antiinflammatory agents)

IT Antiarteriosclerotics
(antiatherosclerotics; preparation of heterocyclyl arylamides and ureas as antiinflammatory agents)

IT Lung, disease
(chronic obstructive, treatment; preparation of heterocyclyl arylamides and ureas as antiinflammatory agents)

IT Dermatitis
(contact, treatment; preparation of heterocyclyl arylamides and ureas as antiinflammatory agents)

IT Inflammation
Intestine, disease
(enterocolitis, treatment; preparation of heterocyclyl arylamides and ureas as antiinflammatory agents)

IT Heart, disease
(failure, treatment; preparation of heterocyclyl arylamides and ureas as antiinflammatory agents)

IT Inflammation

Kidney, disease
(glomerulonephritis, treatment; preparation of heterocyclyl arylamides and ureas as antiinflammatory agents)

IT Transplant and Transplantation
(graft-vs.-host reaction, treatment; preparation of heterocyclyl arylamides and ureas as antiinflammatory agents)

IT Dialysis
(hemodialysis, syndrome treatment; preparation of heterocyclyl arylamides and ureas as antiinflammatory agents)

IT Heart, disease
(infarction, treatment; preparation of heterocyclyl arylamides and ureas as antiinflammatory agents)

IT Reperfusion
(injury, treatment; preparation of heterocyclyl arylamides and ureas as antiinflammatory agents)

IT Analgesics
Anti-Alzheimer's agents
Antiarthritics
Antiasthmatics
Antidiabetic agents
Human
(preparation of heterocyclyl arylamides and ureas as antiinflammatory agents)

IT Injury
(reperfusion, treatment; preparation of heterocyclyl arylamides and ureas as antiinflammatory agents)

IT Bone
(resorption, treatment; preparation of heterocyclyl arylamides and ureas as antiinflammatory agents)

IT Tumor necrosis factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(secretion inhibitors; preparation of heterocyclyl arylamides and ureas as antiinflammatory agents)

IT Brain, disease
(stroke, treatment; preparation of heterocyclyl arylamides and ureas as antiinflammatory agents)

IT Shock (circulatory collapse)
(toxic shock syndrome, treatment; preparation of heterocyclyl arylamides and ureas as antiinflammatory agents)

IT Polymorphonuclear leukocyte
(transfusion syndrome treatment; preparation of heterocyclyl arylamides and ureas as antiinflammatory agents)

IT Cytokines
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(treatment of cytokine-mediated disease; preparation of heterocyclyl arylamides and ureas as antiinflammatory agents)

IT Burn
Lupus erythematosus
Meningitis
Multiple sclerosis
Psoriasis
Sepsis
Skin, disease
(treatment; preparation of heterocyclyl arylamides and ureas as antiinflammatory agents)

IT Inflammation
Intestine, disease
(ulcerative colitis, treatment; preparation of heterocyclyl arylamides and ureas as antiinflammatory agents)

IT **294850-71-8P 294851-09-5P 404009-23-0P**
404009-26-3P 404009-31-0P 404009-33-2P
404009-35-4P 404009-37-6P 404009-39-8P
404009-41-2P 404009-43-4P 404009-45-6P

404009-47-8P 404009-49-0P 404009-51-4P
404009-53-6P 404009-55-8P 404009-57-0P
404009-59-2P 404009-61-6P 404009-63-8P
404009-65-0P 404009-67-2P 404009-69-4P
404009-72-9P 404009-74-1P 404009-76-3P
404009-78-5P 404009-80-9P 404009-83-2P
404009-85-4P 404009-87-6P 404009-89-8P
404009-91-2P 404009-93-4P 404009-95-6P
404009-97-8P 404009-99-0P 404010-01-1P
404010-03-3P 404010-05-5P 404010-07-7P
404010-09-9P 404010-11-3P 404010-13-5P
404010-15-7P 404010-17-9P 404010-19-1P
404010-20-4P 404010-22-6P 404010-24-8P
404010-26-0P 404010-28-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclyl arylamides and ureas as antiinflammatory agents)

IT 98-09-9, Benzenesulfonyl chloride 110-91-8, Morpholine, reactions 500-22-1, 3-Pyridinecarboxaldehyde 591-19-5 624-28-2 683-57-8 930-68-7, 2-Cyclohexen-1-one 1072-72-6 1072-97-5 1445-73-4 1899-24-7 1943-83-5 2298-07-9 3535-88-4 5222-73-1 5396-38-3, 4-tert-Butylanisole 5414-19-7 29943-42-8 89364-31-8 168169-11-7 294851-95-9 294853-07-9 404011-03-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of heterocyclyl arylamides and ureas as antiinflammatory agents)

IT 6309-59-7P 21926-00-1P 71897-83-1P 77055-30-2P 79710-86-4P 197846-82-5P 294851-91-5P 294851-99-3P 294852-01-0P 294852-03-2P 294852-07-6P 294852-70-3P 294852-71-4P 294852-73-6P 294852-75-8P 294852-76-9P 294852-78-1P 294852-80-5P 294852-84-9P 294852-86-1P 294852-90-7P 294852-92-9P 294852-94-1P 294852-96-3P 404010-31-7P 404010-33-9P 404010-35-1P 404010-37-3P 404010-39-5P 404010-41-9P 404010-48-6P 404010-62-4P 404010-66-8P 404010-72-6P 404010-75-9P 404010-77-1P 404010-78-2P 404010-79-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclyl arylamides and ureas as antiinflammatory agents)

IT **294850-71-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclyl arylamides and ureas as antiinflammatory agents)

RN 294850-71-8 HCAPLUS
CN Methanesulfonamide, N-[5-(1,1-dimethylethyl)-2-methoxy-3-[[[[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]amino]carbonyl]amino]phenyl]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L67 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:666713 HCAPLUS
DN 133:252426
ED Entered STN: 22 Sep 2000
TI Preparation of aromatic heterocyclic ureas as antiinflammatory agents
IN Betageri, Rajashehar; **Breitfelder, Steffen**; **Cirillo, Pier F.**; **Gilmore, Thomas A.**; Hickey, Eugene R.; Kirrane, Thomas M.; Moriak, Monica H.; Moss, Neil; **Patel, Usha R.**; **Proudfoot, John R.**; Regan, John R.; **Sharma, Rajiv**; Sun, Sanxing; **Swinamer, Alan D.**; **Takahashi, Hidenori**
PA **Boehringer Ingelheim Pharmaceuticals, Inc., USA**
SO PCT Int. Appl., 282 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07D231-38
ICS C07D213-38; C07D213-74; A61K031-44; A61K031-50; A61K031-415;

A61K031-505; C07D401-14; C07D405-12; C07D401-12; C07D213-76;
C07D409-12; C07D493-08; C07D495-08; A61P029-00; C07D493-08;
C07D307-00; C07D209-00; C07D495-08; C07D333-00

CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000055139	A2	20000921	WO 2000-US3865	20000216 <--
	WO 2000055139	A3	20010426		
	W: AE, AU, BG, BR, BY, CA, CN, CZ, EE, HR, HU, ID, IL, IN, JP, KR, KZ, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, UZ, VN, YU, ZA				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2362003	AA	20000921	CA 2000-2362003	20000216 <--
	EP 1165516	A2	20020102	EP 2000-907295	20000216 <--
	EP 1165516	B1	20041006		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000008922	A	20020115	BR 2000-8922	20000216 <--
	TR 200102817	T2	20020521	TR 2001-200102817	20000216 <--
	JP 2002539198	T2	20021119	JP 2000-605569	20000216 <--
	EE 200100483	A	20021216	EE 2001-483	20000216 <--
	NZ 514711	A	20040227	NZ 2000-514711	20000216 <--
	AU 771273	B2	20040318	AU 2000-28817	20000216 <--
	EP 1466906	A1	20041013	EP 2004-16841	20000216 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
	AT 278674	E	20041015	AT 2000-907295	20000216 <--
	RU 2242474	C2	20041220	RU 2001-126337	20000216 <--
	BG 105880	A	20020531	BG 2001-105880	20010905 <--
	ZA 2001007446	A	20020910	ZA 2001-7446	20010910 <--
	HR 2001000665	A1	20030630	HR 2001-665	20010910 <--
	NO 2001004412	A	20010911	NO 2001-4412	20010911 <--
	US 2002055507	A1	20020509	US 2001-962709	20010925 <--
	US 6660732	B2	20031209		
	US 2002082256	A1	20020627	US 2001-962057	20010925 <--
	US 6656933	B2	20031202		
	HK 1043127	A1	20041224	HK 2002-104955	20020702 <--
	US 2003225077	A1	20031204	US 2003-424613	20030428 <--
	US 2004019038	A1	20040129	US 2003-624289	20030721 <--
PRAI	US 1999-124148P	P	19990312 <--		
	US 1999-165867P	P	19991116 <--		
	EP 2000-907295	A3	20000216		
	US 2000-505582	A3	20000216 <--		
	WO 2000-US3865	W	20000216 <--		
	US 2001-962057	A1	20010925 <--		
	US 2001-962709	A3	20010925 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2000055139	ICM	C07D231-38
	ICS	C07D213-38; C07D213-74; A61K031-44; A61K031-50; A61K031-415; A61K031-505; C07D401-14; C07D405-12; C07D401-12; C07D213-76; C07D409-12; C07D493-08; C07D495-08; A61P029-00; C07D493-08; C07D307-00; C07D209-00; C07D495-08; C07D333-00
EP 1466906	ECLA	C07D213/38; C07D213/74D4; C07D213/76; C07D231/38B3D; C07D401/12+213+209C; C07D401/12+231+213; C07D401/12+241+213; C07D401/12+241B+213; C07D401/14+239B+231+213; C07D405/12+307+213; C07D405/12+307B+231; C07D409/12+335+213;

C07D493/08+307B+209B; C07D495/08+333B+209B <--
US 2002055507 ECLA C07D213/38; C07D213/74D4; C07D213/76; C07D231/38B3D;
C07D307/12; C07D307/52; C07D401/12+213+29C;
C07D401/12+213+211; C07D401/12+231+213;
C07D401/12+241B+213; C07D401/12+241+213;
C07D401/1+239B+231+213; C07D405/12+307+213;
C07D405/12+307B+231; C07D405/12+309+213;
C07D409/12+335+213; C07D493/08+307B+209B;
C07D495/08+333B+209B <--
US 2002082256 ECLA C07D213/38; C07D401/12+213+211; C07D401/12+231+213;
C07D401/12+241B+213; C07D401/12+241+213;
C07D405/12+307+213; C07D405/12+307B+231;
C07D405/12+309+213; C07D409/12+35+213;
C07D493/08+307B+209B; C07D495/08+333B+209B;
C07D213/74D4; C07D213/76; C07D231/38B3D; C07D307/52;
C07D401/12+213+209C <--
US 2004019038 ECLA C07D213/38; C07D213/74D4; C07D213/76; C07D231/38B3D;
C07D307/12; C07D307/52; C07D401/12+213+29C;
C07D401/12+213+211; C07D401/12+231+213;
C07D401/12+241B+213; C07D401/12+241+213;
C07D401/1+239B+231+213; C07D405/12+307+213;
C07D405/12+307B+231; C07D405/12+309+213;
C07D409/12+335+213; C07D493/08+307B+209B;
C07D495/08+333B+209B <--

OS MARPAT 133:252426

GI



I



II

AB The title compds. (I) [wherein Ar1 = (un)substituted pyrrole, pyrrolidine, pyrazole, imidazole, oxazole, thiazole, furan, or thiophene; Ar2 = (un)substituted Ph, (tetrahydro)naphthyl, (tetrahydro)quinoline, (tetrahydro)isoquinoline, benzimidazole, benzofuran, indanyl, indenyl, or indole; W = O or S; X = (un)substituted cycloalkyl, cycloalkenyl, Ph, furan, thiophene, pyrrole, imidazolyl, pyridine, pyrimidine, (dihydro)pyridinone, (dihydro)maleimide, piperidine, piperazine, or pyrazine; Y = a bond or (un)substituted saturated or unsatd. alkyl optionally interrupted by O, NH, S(O), SO2, or S; Z = (un)substituted Ph, pyridine, pyrimidine, pyridazine, imidazole, (tetrahydro)furan, thiophene, (tetrahydro)pyran, 1,3-dioxolanone, 1,3-dioxanone, 1,4-dioxane,

(thio)morpholine (sulfoxide), piperidine, cyclohexanone, pentamethylene sulfoxide, etc.] were prepared for the treatment of diseases or pathol. conditions involving inflammation, such as chronic inflammatory diseases. Thus, coupling 2-cyclohexenone with 4-bromo-1-naphthylamine in the presence of Pd(PPh3)2Cl2, DPPP, and NaHCO3 in DMF, followed by conversion of the amine to an isocyanate using ClCOCl and immediate addition of 1-(4-methylphenyl)-3-tert-butyl-1H-pyrazol-5-amine, gave the urea II. In a cytokine production inhibition assay, preferred compds. of the invention showed IC50 < 10 μM against TNF-α in lipopolysaccharide stimulated THF cells.

ST arom heterocyclic urea prepn antiinflammatory agent; pyrazolyl arom urea prepn tumor necrosis factor inhibitor; urea arom heterocyclic prepn cytokine inhibitor

IT Anti-inflammatory agents
(preparation of aromatic heterocyclic urea antiinflammatory agents by conversion of arylamines to isocyanates followed by addition of heterocyclic amines)

IT Tumor necrosis factors
RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)
(preparation of aromatic heterocyclic urea antiinflammatory agents by conversion of arylamines to isocyanates followed by addition of heterocyclic amines)

IT 294851-78-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of aromatic heterocyclic urea antiinflammatory agents by conversion of arylamines to isocyanates followed by addition of heterocyclic amines)

IT 294848-43-4P 294848-46-7P 294848-49-0P 294848-51-4P 294848-53-6P
294848-55-8P 294848-58-1P 294848-61-6P 294848-64-9P 294848-67-2P
294848-70-7P 294848-73-0P 294848-76-3P 294848-79-6P 294848-82-1P
294848-85-4P 294848-88-7P 294848-91-2P 294848-94-5P 294848-96-7P
294848-98-9P 294849-00-6P 294849-02-8P 294849-04-0P 294849-06-2P
294849-08-4P 294849-10-8P 294849-12-0P 294849-14-2P 294849-16-4P
294849-18-6P 294849-20-0P 294849-22-2P 294849-24-4P 294849-26-6P
294849-28-8P 294849-30-2P 294849-32-4P 294849-34-6P 294849-36-8P
294849-38-0P 294849-40-4P 294849-42-6P 294849-44-8P 294849-46-0P
294849-48-2P 294849-50-6P 294849-52-8P 294849-54-0P 294849-56-2P
294849-58-4P 294849-60-8P 294849-62-0P 294849-64-2P 294849-66-4P
294849-68-6P 294849-70-0P **294849-72-2P** **294849-74-4P**
294849-76-6P **294849-78-8P** **294849-80-2P**
294849-82-4P **294849-84-6P** 294849-86-8P
294849-88-0P 294849-90-4P **294849-92-6P**
294849-94-8P **294849-97-1P** **294850-00-3P**
294850-02-5P **294850-04-7P** **294850-06-9P**
294850-09-2P 294850-12-7P **294850-15-0P**
294850-18-3P **294850-21-8P** **294850-24-1P**
294850-27-4P **294850-29-6P** **294850-31-0P**
294850-33-2P **294850-35-4P** **294850-37-6P**
294850-39-8P **294850-41-2P** **294850-43-4P**
294850-45-6P **294850-47-8P** **294850-49-0P**
294850-51-4P **294850-53-6P** **294850-55-8P**
294850-57-0P **294850-59-2P** 294850-61-6P
294850-63-8P **294850-65-0P** **294850-67-2P**
294850-69-4P **294850-71-8P** **294850-73-0P**
294850-76-3P **294850-79-6P** **294850-81-0P**
294850-84-3P **294850-87-6P** 294850-90-1P **294850-93-4P**
294850-96-7P **294850-99-0P** 294851-02-8P
294851-05-1P 294851-07-3P **294851-09-5P**
294851-11-9P **294851-14-2P** 294851-16-4P

294851-18-6P 294851-20-0P 294851-22-2P
294851-24-4P 294851-26-6P 294851-28-8P
294851-30-2P 294851-32-4P 294851-34-6P
294851-36-8P 294851-38-0P 294851-40-4P
294851-42-6P 294851-44-8P **294851-46-0P**
294851-48-2P 294851-50-6P 294851-52-8P
294851-54-0P 294851-56-2P 294851-58-4P
294851-60-8P 294851-62-0P **294851-64-2P**
294851-66-4P 294851-68-6P 294851-70-0P
294851-72-2P 294851-74-4P **294851-76-6P** 294851-79-9P
294851-81-3P 294851-83-5P 294851-85-7P 294851-87-9P 294853-11-5P
294855-56-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aromatic heterocyclic urea antiinflammatory agents by conversion of arylamines to isocyanates followed by addition of heterocyclic amines)

IT 59-48-3, Oxindole 68-12-2, reactions 75-97-8 95-92-1, Diethyloxalate 109-77-3, Malononitrile 110-91-8, Morpholine, reactions 353-07-1, 2-Cyanoethylhydrazine 500-22-1, Pyridine-3-carboxaldehyde 585-34-2, 3-tert-Butylphenol 591-19-5, 3-Bromoaniline 624-28-2, 2,5-Dibromopyridine 626-35-7, Ethyl nitroacetate 628-22-8, 3-Cyano-1-propanol 930-68-7, 2-Cyclohexenone 1072-72-6, Tetrahydro-1,4-thiopyrone 1072-97-5, 2-Amino-5-bromopyridine 1445-73-4, 1-Methyl-4-piperidone 1461-22-9, Tributyltin chloride 1899-24-7, 5-Bromo-2-furaldehyde 2298-07-9, 4-Bromo-1-naphthylamine 3549-23-3, Methyl 4-t-butylphenylacetate 4097-49-8, 4-tert-Butyl-2,6-dinitrophenol 5292-43-3, tert-Butyl bromoacetate 5414-19-7, Bis(2-bromoethyl) ether 6628-77-9, 5-Amino-2-methoxypyridine 7693-46-1, 4-Nitrophenylchloroformate 29943-42-8, Tetrahydro-4-pyranone 35944-64-0, 3-Iodo-4-methylphenylamine 59997-51-2, 4,4-Dimethyl-3-oxopentanenitrile 62559-08-4, 4-tert-Butyl-2-nitrotoluene 89364-31-8, Tetrahydro-3-furoic acid 155959-13-0, 2-tert-Butyl-6-chloro-5-methylpyridine-4-carboxylic acid methyl ester 168169-11-7 285984-25-0 285984-47-6 294853-00-2 294853-07-9 294853-09-1, 5-tert-Butyl-2-methoxyphenylacetic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of aromatic heterocyclic urea antiinflammatory agents by conversion of arylamines to isocyanates followed by addition of heterocyclic amines)

IT 1914-02-9P 4210-60-0P 6309-59-7P 14011-21-3P 16078-32-3P 19155-24-9P 21905-78-2P 21926-00-1P 29682-15-3P 31181-90-5P 32857-63-9P 71897-83-1P 72934-84-0P 79710-86-4P 83405-70-3P 88905-15-1P 99170-18-0P 116584-61-3P 116584-62-4P 160664-95-9P 197846-82-5P 229003-11-6P 261711-84-6P 294851-89-1P 294851-91-5P 294851-93-7P 294851-95-9P 294851-97-1P 294851-99-3P 294852-01-0P 294852-03-2P **294852-05-4P** 294852-07-6P 294852-09-8P 294852-12-3P 294852-14-5P 294852-18-9P 294852-20-3P 294852-22-5P 294852-24-7P 294852-26-9P 294852-28-1P 294852-30-5P 294852-32-7P 294852-35-0P 294852-37-2P 294852-39-4P 294852-41-8P 294852-43-0P 294852-45-2P 294852-47-4P 294852-49-6P 294852-50-9P 294852-52-1P 294852-54-3P 294852-59-8P 294852-61-2P 294852-64-5P 294852-66-7P 294852-68-9P 294852-70-3P 294852-71-4P 294852-73-6P 294852-75-8P 294852-76-9P 294852-78-1P 294852-80-5P 294852-82-7P 294852-84-9P 294852-86-1P 294852-88-3P 294852-90-7P 294852-92-9P 294852-94-1P 294852-96-3P 294852-98-5P 294853-13-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aromatic heterocyclic urea antiinflammatory agents by conversion of arylamines to isocyanates followed by addition of heterocyclic amines)

IT **294849-72-2P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aromatic heterocyclic urea antiinflammatory agents by conversion of arylamines to isocyanates followed by addition of heterocyclic amines)

RN 294849-72-2 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)phenyl]-N'-[4-[6-(4-morpholinylmethyl)-3-pyridinyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



=>